

3-17-00

A

PATENT

Attorney Docket No. SALK1320-3

☐ NEW PATENT APPLICATION
☐ CONTINUATION-IN-PART
☒ DIVISIONAL

ASSISTANT COMMISSIONER
 FOR PATENTS
 Box Patent Application
 Washington, D.C. 20231

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NO. **EL476992465US**

DATE OF DEPOSIT **March 15, 2000** I HEREBY
 CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED
 STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE
 UNDER 37 C.F.R. 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO
 THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231

MIKHAIL BAYLEY

(TYPE OR PRINTED NAME OF PERSON MAILING PAPER OR FEE)

William A. Seagraves *Bayley*
 SIGNATURE OF PERSON MAILING PAPER OR FEE

JC542 U.S. PTO
 09/526298

03/15/00

Sir:

Transmitted herewith for filing is the divisional patent application of:

Inventor(s): **Ronald M. Evans, Michael B. McKeown, Anthony E. Oro,
 William A. Seagraves, and Tso-Pang Yao**

For: **MULTIMERIC FORMS OF MEMBERS OF THE STEROID/THYROID
 SUPERFAMILY OF RECEPTORS WITH THE ULTRASPIRACLE
 RECEPTOR**

This is a request for filing a ____ continuation ☒ divisional of application Serial
 No. 08,464,514, filed on June 5, 1995, now pending, which is a divisional of application Serial
 No. 07/907,908, filed on July 2, 1992, now abandoned;

FULL NAME OF FIRST INVENTOR	LAST NAME: Evans	FIRST NAME: Ronald	MIDDLE NAME: M.
CITIZENSHIP	STATE OR FOREIGN COUNTRY: United States		
POST OFFICE ADDRESS	POST OFFICE ADDRESS: 8615 La Jolla Scenic Road, North	CITY AND STATE: La Jolla, California	ZIP CODE: 92037
FULL NAME OF SECOND INVENTOR	LAST NAME: McKeown	FIRST NAME: Michael	MIDDLE NAME: B.
CITIZENSHIP	STATE OR FOREIGN COUNTRY: United States		
POST OFFICE ADDRESS	POST OFFICE ADDRESS: 3083 Fried Avenue	CITY AND STATE: San Diego, California	ZIP CODE: 92122

In re Application of:
Evans, et al.
Application No.: Unassigned
Filed: March 15, 2000
Page 2

PATENT
Attorney Docket No.: SALK1320-3

FULL NAME OF THIRD INVENTOR	LAST NAME: Oro	FIRST NAME: Anthony	MIDDLE NAME: E.
CITIZENSHIP	STATE OR FOREIGN COUNTRY: United States		
POST OFFICE ADDRESS	POST OFFICE ADDRESS: 10710 Escobar Drive	CITY AND STATE: San Diego, California	ZIP CODE: 92124
FULL NAME OF FOURTH INVENTOR	LAST NAME: Seagraves	FIRST NAME: William	MIDDLE NAME: A.
CITIZENSHIP	STATE OR FOREIGN COUNTRY: United States		
POST OFFICE ADDRESS	POST OFFICE ADDRESS: 416 Meetinghouse Road	CITY AND STATE: Ambler, Pennsylvania	ZIP CODE: 19002
FULL NAME OF FIFTH INVENTOR	LAST NAME: Yao	FIRST NAME: Tso-Pang	MIDDLE NAME:
CITIZENSHIP	STATE OR FOREIGN COUNTRY: Taiwan		
POST OFFICE ADDRESS	POST OFFICE ADDRESS: 3765G Miramar Street	CITY AND STATE: La Jolla, California	ZIP CODE: 92037

The issue fee has been paid in the above-identified application, however, it is not yet issued.

1. X Cancel in this application original claims 1-13, 22 and 26-34 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
2. X A preliminary amendment is enclosed.

In re Application of:

Evans, et al.

Application No.: Unassigned

Filed: March 15, 2000

Page 3

PATENT

Attorney Docket No.: SALK1320-3

The filing fee has been calculated as shown below:

For	Number Filed		Number Extra		Rate			Fee	
					Small Entity	Other Entity		Small Entity	Other Entity
Total Claims	25 - 20	=	5	X	\$09	\$18	=	\$ 45.00	\$.00
Independent Claims	6 - 3	=	3	X	\$39	\$78	=	\$ 117.00	\$.00
Multiple Dependent Claims Presented: ___ Yes <u>X</u> No					\$130	\$260			\$.00
BASIC FEE					\$345	\$690		\$ 345.00	\$.00
TOTAL FEE								\$ 507.00	\$.00

3. X The Assistant Commissioner is hereby authorized to charge a total payment of \$507.00; which includes \$345.00 for the filing fee; \$162.00 for eight (8) additional claims, and any other fees associated with this communication or credit any overpayment to Deposit Account No. 07-1895. A duplicate copy of this Transmittal Sheet is enclosed.
- X Any additional filing fees required under 37 C.F.R. 1.16.
- X Any patent application processing fees under 37 C.F.R. 1.17.
4. X Amend the specification by inserting before the first paragraph on page 1:
- This application is a ___ continuation X divisional of application Serial No. 08,464,514, filed on June 5, 1995, now pending, which is a divisional of application Serial No. 07/907,908, filed on July 2, 1992, now abandoned; the entire contents of each of which are hereby incorporated by reference herein.
5. X A verified statement claiming small entity status was filed in parent application Serial No. 08/464,514, filed June 5, 1995, and such status is still proper.
6. X The prior application is assigned of record to The Salk Institute for Biological Studies.
7. X The power of attorney in the prior application is to Stephen E. Reiter, Registration No. 31,192.
8. X Copy of associate power of attorney is enclosed.
9. X Please transfer the drawings from the prior application to the new application.

In re Application of:
Evans, et al.
Application No.: Unassigned
Filed: March 15, 2000
Page 4

PATENT
Attorney Docket No.: SALK1320-3

10. X Information Disclosure Statements filed in the prior application under 37 C.F.R. 1.97 are hereby made of record (copies of 1449's and 892's are enclosed herewith for the Examiner's convenience).
11. X Please transfer the computer readable form (CRF) of the Sequence Listing from the prior application, which CRF was filed with a Communication mailed October 22, 1999, to this new application.
12. X Please transfer the Statement under 37 C.F.R. § 1.821(f) and (g) from the prior application, which Statement was filed with a Communication mailed October 22, 1999, to this new application.
13. X A true copy of the prior application as filed is enclosed, including the Declaration and Power of Attorney filed in parent application, U.S. Serial No. 07/907,908, filed July 2, 1992.


Address all future communications to:

Stephen E. Reiter
GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1600
San Diego, California 92121-2189
Telephone: (858) 677-1409
Facsimile: (858) 677-1465

The undersigned states that the enclosed application papers comprise a true copy of the prior application as filed.

Respectfully submitted,

Date: March 15, 2000



Stephen E. Reiter
Attorney for Applicant
Registration No. 31,192
Phone: (858) 677-1409
Fax: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1600
San Diego, CA 92121-2189

Gray Cary\GT\6166817.1
62574-990000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Evans, et al.

Application No.: Unassigned

Filed: March 15, 2000

For: MULTIMERIC FORMS OF MEMBERS
OF THE STEROID/THYROID
SUPERFAMILY OF RECEPTORS
WITH THE ULTRASPIRACLE
RECEPTOR

) Group Art Unit: Unassigned

) Examiner: Unassigned

) CERTIFICATE OF MAILING BY "EXPRESS MAIL"


) "EXPRESS MAIL" MAILING LABEL NO.

) **EL476992465US** DATE OF DEPOSIT,

) **March 15, 2000**, I HEREBY CERTIFY THAT THIS
PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED
STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE
TO ADDRESSEE" SERVICE UNDER 37 C.F.R. 1.10 ON THE
DATE INDICATED ABOVE AND IS ADDRESSED TO THE
ASSISTANT COMMISSIONER FOR PATENTS,
WASHINGTON, D.C. 20231

) **MIKHAIL BAYLEY**

) (Name of person mailing paper)

) 

) Signature

March 15, 2000
Date

Box Patent Application
Assistant Commissioner of Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

This Preliminary Amendment is being filed prior to examination of the
above-identified application. This Amendment accompanies a request under 37 C.F.R. § 1.53(b)
to file a divisional application based on Application No. 08/464,514, filed June 5, 1995, now
pending.

In the Claims

Please cancel claims 20, 21 and 23-25. Please introduce new claims 35-53 as follows:

35. (New) A method of inducing the expression of an exogenous gene in a subject containing:
- a) a DNA construct encoding an exogenous gene product under the control of a hormone response element; wherein said response element is not normally present in the cells of said subject,
 - b) DNA encoding a receptor which is not normally present in the cells of said subject, under the control of an inducible promoter; wherein said receptor, in the presence of its associated ligand and the ultraspiracle receptor, binds to said hormone response element,
 - c) ultraspiracle receptor, and
 - d) the associated ligand for said receptor which is not normally present in the cells of said subject,
- said method comprising subjecting a subject to conditions suitable to induce expression of said receptor which is not normally in the cells of said subject.
36. (New) A method according to claim 35, wherein said ultraspiracle receptor is provided to said subject by a DNA construct encoding said ultraspiracle receptor.
37. (New) A method according to claim 36, wherein said receptors are expressed under the control of a tissue-specific promoter.
38. (New) A method according to claim 35, wherein said ultraspiracle receptor is substantially the same as that set forth in amino acids 1-513 of SEQ ID NO:2.
39. (New) A method according to claim 35, wherein said exogenous genes are wild type genes or therapeutic genes.
40. (New) A method according to claim 39, wherein said wild type genes encode gene products:

- a) the substantial absence of which leads to the occurrence of a non-normal state in said subject, or
- b) a substantial excess of which leads to the occurrence of a non-normal state in said subject.

41. (New) A method according to claim 39, wherein said therapeutic genes encode gene products:

- a) which are toxic to the cells in which they are expressed, or
- b) which impart a beneficial property to said subject.

42. (New) A method of inducing expression of an exogenous gene product in a subject containing a DNA construct encoding said product under the control of a hormone response element; wherein said response element is not normally present in the cells of said subject, said method comprising introducing into said subject:

- a) a receptor which is not normally present in the cells of said subject; wherein said receptor, in combination with its associated ligand and ultraspiracle receptor, binds to said hormone response element, activating transcription therefrom,
- b) the ultraspiracle receptor, and
- c) the associated ligand for said receptor.

43. (New) A method according to claim 42, wherein said receptor not normally present in the cells of said subject and said ultraspiracle receptor are provided to said subject by DNA construct(s) encoding said receptors.

44. (New) A method according to claim 43, wherein said receptors are expressed under the control of a tissue-specific promoter.

45. (New) A method according to claim 42, wherein said ultraspiracle receptor is substantially the same as that set forth in amino acids 1-513 of SEQ ID NO:2.
46. (New) A method according to claim 42, wherein said exogenous genes are wild type genes or therapeutic genes.
47. (New) A method according to claim 46, wherein said wild type genes encode gene products:
- a) the substantial absence of which leads to the occurrence of a non-normal state in said subject, or
 - b) a substantial excess of which leads to the occurrence of a non-normal state in said subject.
48. (New) A method according to claim 46, wherein said therapeutic genes encode gene products:
- a) which are toxic to the cells in which they are expressed, or
 - b) which impart a beneficial property to said subject.
49. (New) A method to distinguish the physiological effect of a first hormone receptor in a host from other hormone receptors in said host which respond to the same ligand, said method comprising:
- a) replacing the ligand binding domain of said first receptor with a ligand binding domain from an exogenous receptor to produce a chimeric receptor maintained under the control of a tissue specific promoter;
- wherein said exogenous receptor and the ligand to which the exogenous receptor responds are not normally present in said host; and

wherein said exogenous receptor, in the presence of its associated ligand,
binds to a hormone response element, thereby activating said
response element, and thereafter

b) monitoring the production of product(s) whose expression is controlled by
said first hormone receptor when said host is exposed to ultraspiracle receptor and
ligand to which said exogenous receptor responds.

50. (New) A method to render mammalian hormone receptor(s) uniquely responsive to a
ligand not endogenous to host(s) in which said receptor is normally found, said method
comprising:

a) replacing the ligand binding domain of said receptor with a ligand binding
domain from a second receptor;

wherein said second receptor is not normally present in said host; and wherein the ligand to
which the second receptor responds is not normally present in said host.

51. (New) A method according to claim 50, wherein said second receptor is ultraspiracle
receptor.

52. (New) A method according to claim 50, wherein said ultraspiracle receptor has an amino
acid sequence that is substantially the same as that set forth in amino acids 1-513 of SEQ ID
NO:2.

53. (New) A method to determine the ligand(s) to which orphan receptor(s) responds, said
method comprising:

monitoring a host cell containing a reporter construct and a hybrid
receptor for expression of product(s) of said reporter construct upon contacting
said cell with potential ligands for said orphan receptor and the ultraspiracle
receptor;

wherein said reporter construct comprises a gene encoding
a reporter molecule, operatively linked for transcription to a steroid or steroid-like
hormone response element; wherein said response element is not normally present
in the cells of said host;

wherein said hybrid receptor comprises:

the N-terminal domain and DNA binding domain of a member of the
steroid/thyroid superfamily of receptors, wherein said member is not normally
present in the host cells, and wherein said member, in the presence of its
associated ligand and ultraspiracle receptor, binds said response element,
activating transcription therefrom, and
the ligand binding domain of said orphan receptor.

Remarks

By the present communication, claims 20, 21 and 23-25 have been canceled, and new
claims 35-53 have been introduced. No new matter is introduced as the new claim language is
fully supported by Applicants' specification and original claims.

Accordingly, claims 14-19 and 35-53 are pending.


In re Application of:
Evans, et al.
Application No.: Unassigned
Filed: March 15, 2000
Page 7

PATENT
Attorney Docket No. SALK1320-3

It is respectfully submitted that the claims submitted herewith are in condition for allowance. Accordingly, prompt and favorable action on all pending claims are respectfully requested. If any questions or issues remain, the Examiner is invited to contact the undersigned at the telephone number set forth below so that a prompt disposition of this application can be achieved.

Respectfully submitted,

Date: March 15, 2000



Stephen E. Reiter
Reg. No. 31,192
Telephone: (858) 677-1409
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1600
San Diego, California 92121-2189

Gray Cary\
GT\6172372.1
62574-159373

005764-66292560

A P P L I C A T I O N

for

UNITED STATES LETTERS PATENT

on

MULTIMERIC FORMS OF MEMBERS OF
THE STEROID/THYROID SUPERFAMILY OF RECEPTORS
WITH THE ULTRASPIRACLE RECEPTOR

by

Ronald M. Evans,
Michael B. McKeown,
Anthony E. Oro,
William A. Segraves, and
Tso-Pang Yao

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NUMBER 18898702729

DATE OF DEPOSIT 7/2/92

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH
THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO
ADDRESSEE" SERVICE UNDER 37 CFR 1-10 ON THE DATE INDICATED
ABOVE AND IS ADDRESSED TO THE COMMISSIONER OF PATENTS AND
TRADEMARKS, WASHINGTON, D.C. 20231.

Number of Drawings: Two

Docket No.: P41 9321

Salk File No.: S92009

RUTH I. SABULA

(TYPED OR PRINTED NAME OF PERSON MAILING PAPER OR FEE)

Ruth I. Sabula

(SIGNATURE OF PERSON MAILING PAPER OR FEE)

Attorneys

Pretty, Schroeder, Brueggemann & Clark
444 South Flower Street, Suite 2000
Los Angeles, California 90071

MULTIMERIC FORMS OF MEMBERS OF
THE STEROID/THYROID SUPERFAMILY OF RECEPTORS
WITH THE ULTRASPIRACLE RECEPTOR

RELATED APPLICATIONS

This application is a continuation-in-part of
United States Application Serial Number 07/497,935, filed
5 March 22, 1990, now pending.

FIELD OF THE INVENTION

10 The present invention relates to interactions
between members of the steroid/thyroid superfamily of
receptor proteins, novel combinations of various members of
the steroid/thyroid superfamily of receptor proteins, and
methods of using such combinations.

15 BACKGROUND OF THE INVENTION

Transcriptional regulation of development and
homeostasis in complex eukaryotes, including humans and
other mammals, birds, fish, insects, and the like, is
20 controlled by a wide variety of regulatory substances,
including steroid and thyroid hormones. These hormones
exert potent effects on development and differentiation of
phylogenetically diverse organisms. The effects of
hormones are mediated by interaction with specific, high
25 affinity binding proteins referred to as receptors.

A number of receptor proteins are known, each
specific for steroid hormones (e.g., estrogens (estrogen
receptor), progesterones (progesterone receptor),
30 glucocorticoid (glucocorticoid receptor), androgens
(androgen receptor), aldosterones (mineralocorticoid
receptor), vitamin D (vitamin D receptor)], retinoids
(e.g., retinoic acid receptor) or thyroid hormones (e.g.,
thyroid hormone receptor). Receptor proteins have been

found to be distributed throughout the cell population of complex eukaryotes in a tissue specific fashion.

Molecular cloning studies have made it possible
5 to demonstrate that receptors for steroid, retinoid and thyroid hormones are all structurally related and comprise a superfamily of regulatory proteins. These regulatory proteins are capable of modulating specific gene expression in response to hormone stimulation by binding directly to
10 cis-acting elements.

It is known that steroid or thyroid hormones, protected forms thereof, or metabolites thereof, enter cells and bind to the corresponding specific receptor
15 protein, initiating an allosteric alteration of the protein. As a result of this alteration, the complex of receptor and hormone (or metabolite thereof) is capable of binding with high affinity to certain specific sites on chromatin. One of the primary effects of steroid and
20 thyroid hormones is an increase in transcription of a subset of genes in specific cell types.

A number of transcriptional control units which are responsive to members of the steroid/thyroid
25 superfamily of receptors have been identified. These include the mouse mammary tumor virus 5'-long terminal repeat (MTV LTR), responsive to glucocorticoid, aldosterone and androgen hormones; the transcriptional control units for mammalian growth hormone genes, responsive to
30 glucocorticoids, estrogens and thyroid hormones; the transcriptional control units for mammalian prolactin genes and progesterone receptor genes, responsive to estrogens; the transcriptional control units for avian ovalbumin genes, responsive to progesterones; mammalian
35 metallothionein gene transcriptional control units, responsive to glucocorticoids; and mammalian hepatic α_2 -globulin gene transcriptional control units, responsive to

androgens, estrogens, thyroid hormones, and glucocorticoids.

A major obstacle to further understanding and more widespread use of the various members of the steroid/thyroid superfamily of hormone receptors has been a lack of awareness of the possible interactions of various members of the steroid/thyroid superfamily of hormone receptors, and an understanding of the implications of such interactions on the ability of members of the steroid/thyroid superfamily of hormone receptors to exert transcriptional regulation of various physiological processes.

DNA binding studies on the glucocorticoid receptor (GR) and the estrogen receptor (ER) have indicated that these receptors bind to their hormone response elements (HREs) as homodimeric complexes [see, for example, Kumar and Chambon in *Cell* 55:145-156 (1988) and Tsi et al., in *Cell* 55:361-369 (1988)]. However, recent biochemical analysis has revealed that some other receptors (including retinoic acid receptor (RAR), thyroid hormone receptor (TR), and the vitamin D receptor (VDR)) can not efficiently bind to cognate response elements as homodimers, but rather require additional factors present in cell nuclear extracts to achieve high affinity DNA binding [see, for example, Murray and Towle in *Mol. Endocrinol.* 3:1434-1442 (1989), Glass et al., in *Cell* 63:729-738 (1990), Liao et al., in *Proc. Natl. Acad. Sci. USA* 87:9751-9755 (1990), and Yang et al., in *Proc. Natl. Acad. Sci. USA* 88:3559-3563 (1991)].

Several recent reports have identified members of the retinoid X receptor family (RXR; see, for example, Mangelsdorf et al., in *Nature* 345:224-229 (1990) and *Gene Dev.* 6:329-344 (1992), and Leid et al., in *Cell* 68:377-395 (1992)) as factors that can interact with RAR and potentiate DNA binding by forming a novel RAR/RXR

heterodimer [see, for example, Yu et al., in Cell 67:1251-1266 (1991), Klierer et al., in Nature 355:446-449 (1992), Leid et al., supra, and Zhang et al., in Nature 355:441-446 (1992)]. Interestingly, RAR is not the only receptor with which RXR can interact. In fact, RXR has been found to be capable of heterodimerizing with several other members of the nuclear receptor superfamily, including VDR, TR (see Klierer, et al., supra) and peroxisome proliferator-activated receptor (PPAR; see, for example, Issemann and Green in Nature 347: 645-650 (1990)).

Although the physiological significance of these interactions remains to be definitively determined, the capability of nuclear receptors to heterodimerize suggests the existence of an elaborate network through which distinct nuclear hormone receptor classes are capable of modulating each other's activity. In addition, the possible existence of other factors that can potentially interact with members of the steroid/thyroid superfamily and potentiate DNA binding by forming novel heteromeric species remains to be determined.

BRIEF DESCRIPTION OF THE INVENTION

In accordance with the present invention, we have discovered that various members of the steroid/thyroid superfamily of receptors can combine with the insect derived ultraspiracle receptor (or functional fragments thereof comprising at least the dimerization domain thereof) to form a multimeric complex receptor. Accordingly, the combination of a first receptor species with the ultraspiracle receptor (or a truncated form thereof comprising at least the dimerization domain thereof) is capable of modulating the ability of the first receptor species to trans-activate transcription of genes maintained under steroid hormone or hormone-like expression control in the presence of cognate ligand for said first

receptor.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 presents a comparison of amino acid identity for various domains of invention ultraspiracle receptor (usp) in comparison with previously identified receptors human RXR-alpha (hRXR α), human retinoic acid receptor-alpha (hRAR α) and human glucocorticoid receptor (hGR).

Figure 2 presents the % conversion of substrate by chloramphenicol acetyltransferase (CAT) as a result of cotransfection of mammalian (CV1) cells with ecdysone receptor (EcR) encoding vector and/or ultraspiracle receptor (usp) encoding vector along with CAT reporter vector which contains an ecdysone response element (EcRE).

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there are provided multimeric receptor species which belong to the steroid/thyroid superfamily of receptors, comprising at least one member of the steroid/thyroid superfamily of receptors, and the ultraspiracle receptor.

As employed herein, the term "dimerization domain(s)" of a member of the steroid/thyroid superfamily of receptors refers to that portion (or portions) of the receptor which is involved in the formation of a given multimeric complex receptor. Dimerization domain(s) typically comprise at least a portion of the carboxy-terminal portion of the receptor (i.e., the carboxy-terminal portion of a receptor with respect to the DNA-binding domain thereof) and/or at least a portion of the DNA binding domain itself. Multiple domains of a given receptor can act in concert as well as independently.

Combinations contemplated by the present invention can broadly be referred to as "multimeric species", which is intended to embrace all of the various oligomeric forms in which members of the steroid/thyroid superfamily of receptors (including fragments thereof comprising the dimerization domains thereof) are capable of associating with at least the dimerization domain of the ultraspiracle receptor. Thus, reference to "combinations" of steroid receptors or "multimeric" forms of steroid receptors with at least the dimerization domain of the ultraspiracle receptor includes heterodimeric combinations of one member of the steroid/thyroid superfamily of receptors (including fragments thereof comprising the dimerization domain thereof) with at least the dimerization domain of the ultraspiracle receptor, heterotrimeric combinations of one or two members of the steroid/thyroid superfamily of receptors (including fragments thereof comprising the dimerization domains thereof) with at least the dimerization domain of the ultraspiracle receptor, heterotetrameric combinations of one, two or three members of the steroid/thyroid superfamily of receptors (including fragments thereof comprising the dimerization domains thereof) with at least the dimerization domain of the ultraspiracle receptor, and the like.

As employed herein, the term "ultraspiracle receptor" refers to a novel invertebrate polypeptide which has a DNA binding domain of about 66 amino acids with at least 9 Cys residues, more than about 75 % amino acid identity in comparison with the DNA binding domain of hRXR- α (see Mangelsdorf et al., 1990, supra), less than about 60 % amino acid identity in comparison with the DNA binding domain of hGR, and less than about 60% amino acid identify in comparison with the DNA binding domain of hRAR α . Invention polypeptide can be further characterized by having less than 50% (but typically greater than 40%) amino acid identity in comparison with the ligand binding

domain of hRXR-alpha, but less than 25% amino acid identity in comparison with the ligand binding domains of either hGR or hRAR α . A sequence comparison of amino acid identity between invention receptor and several other receptors is presented in Figure 1.

The deduced amino acid sequence for the ultraspiracle receptor is presented in SEQ ID NO:2 [see also, Oro et al., in Nature 347: 298-301 (1990)]. Also contemplated within the scope of the present invention are peptides comprising a DNA binding domain with substantially the same sequence as that of amino acids 104 - 169 shown in SEQ ID NO:2 (i.e., the DNA binding domain of the ultraspiracle receptor). As employed herein, the term "substantially the same amino acid sequence" refers to amino acid sequences having at least about 80% identity with respect to the reference amino acid sequence, and retaining comparable functional and biological properties characteristic of the protein encoded by the reference amino acid sequence. Preferably, proteins having "substantially the same amino acid sequence" will have at least about 90% amino acid identity with respect to the reference amino acid sequence; with greater than about 95% amino acid sequence identity being especially preferred. Also contemplated within the scope of the present invention are polypeptides having substantially the same sequence as that of amino acids 1 - 513 shown in SEQ ID NO:2. A presently preferred polypeptide of the invention is the polypeptide encoded by vector pXR2C8 [see Oro et al., supra].

As employed herein, the phrase "members of the steroid/thyroid superfamily of receptors" refers to all of the various isoforms of hormone binding proteins that operate as ligand-dependent transcription factors, including members of the steroid/thyroid superfamily of receptors for which specific ligands have not yet been

identified (referred to hereinafter as "orphan receptors"). Each such protein has the intrinsic ability to bind to a specific DNA sequence (i.e., regulatory sequence) associated with the target gene. The transcriptional activity of the gene is modulated by the presence or absence of the cognate hormone (ligand) as a result of binding of ligand to receptor, enabling interaction of receptor with the regulatory sequence.

The DNA-binding domains of all members of this superfamily of receptors are related, consisting of 66-68 amino acid residues, and possessing about 20 invariant amino acid residues, including nine cysteines. A member of the superfamily can be characterized as a protein which contains these diagnostic amino acid residues, which are part of the DNA-binding domain of such known steroid receptors as the human glucocorticoid receptor (amino acids 421-486), the estrogen receptor (amino acids 185-250), the mineralocorticoid receptor (amino acids 603-668), the human retinoic acid receptor (amino acids 88-153), and the like. The highly conserved amino acids of the DNA-binding domain of members of the superfamily are as follows:

```

Cys - X - X - Cys - X - X - Asp* - X -
Ala* - X - Gly* - X - Tyr* - X - X -
X - X - Cys - X - X - Cys - Lys* - X -
Phe - Phe - X - Arg* - X - X - X - X -
X - X - X - X - X - (X - X -) Cys - X -
X - X - X - X - (X - X - X -) Cys - X -
X - X - Lys - X - X - Arg - X - X -
Cys - X - X - Cys - Arg* - X - X -
Lys* - Cys - X - X - X - Gly* - Met
(SEQ ID No 3);

```

wherein X designates non-conserved amino acids within the DNA-binding domain; the amino acid residues denoted with an asterisk are residues that are almost universally

conserved, but for which variations have been found in some identified hormone receptors; and the residues enclosed in parenthesis are optional residues (thus, the DNA-binding domain is a minimum of 66 amino acids in length, but can
5 contain several additional residues).

Exemplary members of the steroid/thyroid superfamily of receptors (including the various isoforms thereof) include steroid receptors such as glucocorticoid
10 receptor, mineralocorticoid receptor, progesterone receptor, androgen receptor, vitamin D₃ receptor, and the like; plus retinoid receptors, such as the various isoforms of RAR (e.g., RAR α , RAR β , or RAR γ), the various isoforms of RXR (e.g., RXR α , RXR β , or RXR γ), and the like; thyroid
15 receptors, such as TR α , TR β , and the like; insect derived receptors such as the ecdysone receptor, and the like; as well as other gene products which, by their structure and properties, are considered to be members of the superfamily, as defined hereinabove, including the various
20 isoforms thereof (even though ligands therefor have not yet been identified; such receptors are referred to as "orphan receptors"). Examples of orphan receptors include HNF4 [see, for example, Sladek et al., in *Genes & Development* 4: 2353-2365 (1990)], the COUP family of receptors [see, for
25 example, Miyajima et al., in *Nucleic Acids Research* 16: 11057-11074 (1988), and Wang et al., in *Nature* 340: 163-166 (1989)], COUP-like receptors and COUP homologs, such as those described by Mlodzik et al., in *Cell* 60: 211-224 (1990) and Ladas et al., in *Science* 251: 561-565 (1991),
30 various isoforms of peroxisome proliferator-activated receptors (PPARs; see, for example, Issemann and Green, supra), the insect derived knirps and knirps-related receptors, and the like.

35 The formation of multimeric receptor(s) can modulate the ability of member(s) of the steroid/thyroid superfamily of receptors to trans-activate transcription of

genes maintained under expression control in the presence of ligand for said receptor. The actual effect on activation of transcription (i.e., enhancement or repression of transcription activity) will vary depending on the receptor species which are part of the multimeric receptor, as well as on the response element with which the multimeric species interacts. Thus, for example, formation of a heterodimer of the ecdysone receptor with the ultraspiracle receptor promotes the ability of the ecdysone receptor to induce trans-activation activity in the presence of an ecdysone response element (see, for example, SEQ ID NO:26).

In accordance with another embodiment of the present invention, there is provided a method to modulate, in an expression system, the transcription activation of a gene by a member of the steroid/thyroid superfamily of receptors in the presence of ligand therefor, wherein the expression of said gene is maintained under the control of a hormone response element, said method comprising:

exposing said system to at least the dimerization domain of the ultraspiracle receptor, in an amount effective to form a multimeric complex receptor with said member of the steroid/thyroid superfamily of receptors.

Exposure of said system to at least the dimerization domain of the ultraspiracle receptor is accomplished by directly administering ultraspiracle receptor (or fragments thereof that allow modification of the receptor through the formation of heterodimeric receptor species) to said system, or by exposing said system to compound(s) and/or condition(s) which induce expression of the ultraspiracle receptor (or dimerization domain thereof). The resulting multimeric receptor species is effective to modulate transcription activation of said gene.

As employed herein, the term "modulate" refers to the ability of a given multimeric complex receptor to either enhance or repress the induction of transcription of a target gene by a given receptor, relative to such ability of said receptor in its uncomplexed state. The actual effect of multimerization on the transcription activity of a receptor will vary depending on the specific receptor species which are part of the multimeric complex receptor, and on the response element with which the multimeric complex receptor interacts. Thus, for example, formation of a heterodimer of the ecdysone receptor and the ultraspiracle receptor provides enhanced trans-activation activity with respect to the ability of the ecdysone receptor alone to promote trans-activation. Conversely, formation of a heterodimer of the ecdysone receptor and the dimerization domain of the ultraspiracle receptor should prevent the ability of ecdysone to promote trans-activation activity, since the resulting multimeric complex receptor will have a reduced ability to bind DNA, relative to the ability of ecdysone-usp multimeric complex to bind DNA.

The term "ecdysone" is employed herein in its generic sense (in accordance with common usage in the art), referring to compounds with the appropriate biological activity, in analogy with the terms estrogen or progestin [see, for example, Cherbas et al., in *Biosynthesis, metabolism and mode of action of invertebrate hormones* (ed. J. Hoffmann and M. Porchet), p. 305-322; Springer-Verlag, Berlin]. 20-Hydroxyecdysone is the major naturally occurring ecdysone. Analogs of the naturally occurring ecdysones are also contemplated within the scope of the present invention, such as for example, ponasterone A, 26-iodoponasterone A, muristerone, inokosterone, 26-mesylinokosterone, and the like.

As employed herein, the phrase "hormone response element" refers to short cis-acting sequences (i.e., having

about 20 bp) that are required for hormonal (or ligand) activation of transcription. The attachment of these elements to an otherwise hormone-nonresponsive gene causes that gene to become hormone responsive. These sequences, commonly referred to as hormone response elements (or HREs), function in a position- and orientation-independent fashion. Unlike other enhancers, the activity of HREs can be modulated by the presence or absence of ligand. See, for example, Evans, Science 240: 889-895 (1988), and the references cited therein. In the present specification and claims, the term "hormone response element" is used in a generic sense to mean and embody the functional characteristics implied by all terms used in the art to describe these sequences.

Hormone response elements contemplated for use in the practice of the present invention include naturally occurring response elements as well as modified forms thereof (see, for example, SEQ ID NOS: 7, 12, 15, 25, 26, 28 and 29), as well as synthetic response elements which can be composed of two or more "half sites", wherein each half site comprises the sequence

-RGBNNM-,

wherein

R is selected from A or G;

B is selected from G, C, or T;

each N is independently selected from A, T, C, or G; and

M is selected from A or C;

with the proviso that at least 4 nucleotides of said -RGBNNM- sequence are identical with the nucleotides at corresponding positions of the sequence -AGGTCA-, or the half-sites of ecdysone response elements (EcREs) (see, for example, SEQ ID NOS:26, 28 and 29) and

wherein the nucleotide spacing between each of said half-sites falls in the range of 0 up to 15 nucleotides, N.

When one of the half sites described above is incorporated into a synthetic response element in a direct repeat motif, and such half site varies by 2 nucleotides from the preferred sequence of -AGGTCA-, it is preferred that the other half site of the response element be the same as, or vary from the preferred sequence by no more than 1 nucleotide. It is presently preferred that the 3'-half site (or downstream half site) of a pair of half sites vary from the preferred sequence by at most 1 nucleotide.

When the above-described half sites are combined in direct repeat fashion (rather than as palindromic constructs), the resulting synthetic response elements are referred to as "DR-x", wherein "DR" refers to the direct repeat nature of the association between the half sites, and "x" indicates the number of spacer nucleotides between each half site.

Exemplary response elements useful in the practice of the present invention are derived from various combinations of half sites having sequences selected from, for example, -AGGTCA-, -GGTTCA-, -GGGTTA-, -GGGTGA-, -AGGTGA-, -GGGTCA-, and the like.

The nucleotides employed in a non-zero spacer are independently selected from C, T, G, or A.

Exemplary three nucleotide spacers include -AGG-, -ATG-, -ACG-, -CGA-, and the like. Exemplary four nucleotide spacers include -CAGG-, -GGGG-, -TTTC-, and the like. Exemplary five nucleotide spacers include -CCAGG-, -ACAGG-, -CCGAA-, -CTGAC-, -TTGAC-, and the like.

35

Exemplary response elements contemplated by the present invention include the following DR-3 elements:

5' -AGGTCA-AGG-AGGTCA-3' (SEQ ID No. 4),
 5' -GGGTGA-ATG-AGGACA-3' (SEQ ID No. 5),
 5' -GGGTGA-ACG-GGGGCA-3' (SEQ ID No. 6), and
 5' -GGTTCA-CGA-GGTTCA-3' (SEQ ID No. 7);

the following DR-4 elements:

5' -AGGTCA-CAGG-AGGTCA-3' (SEQ ID No. 8),
 5' -AGGTGA-CAGG-AGGTCA-3' (SEQ ID No. 9),
 5' -AGGTGA-CAGG-AGGACA-3' (SEQ ID No. 10),
 5' -GGGTGA-GGGG-AGGACA-3' (SEQ ID No. 11),

and

5' -GGGTCA-TTTC-AGGTCC-3' (SEQ ID No. 12);

the following DR-5 elements:

5' -AGGTCA-CCAGG-AGGTCA-3' (SEQ ID No. 13),
 5' -AGGTGA-ACAGG-AGGTCA-3' (SEQ ID No. 14),
 5' -GGTTCA-CCGAA-AGTTCA-3' (SEQ ID No. 15),
 5' -GGTTCA-CCGAA-AGTTCA-3' (SEQ ID No. 16),
 5' -AGGTCA-CTGAC-AGGGCA-3' (SEQ ID No. 17),
 5' -GGGTCA-TTCAG-AGTTCA-3' (SEQ ID No. 18),

5' -AAGCTTAAG-GGTTCA-CCGAA-AGTTCA-CTCAGCTT-3' (SEQ ID No. 19),

5' -AAGCTTAAG-GGTTCA-CCGAA-AGTTCA-CTCGCATAGCTT-3' (SEQ ID No. 20), and

5' -AAGCTTAAG-GGTTCA-CCGAA-AGTTCA-CTCGCATATATTAGCTT-3' (SEQ ID No. 21);

the ecdysone responsive elements set forth in SEQ ID NOS: 26, 28 and 29, and the like.

Presently preferred response elements contemplated for use in the practice of the present invention include:

5' -AGGTCA-AGG-AGGTCA-3' (SEQ ID No. 4),
 5' -AGGTCA-CAGG-AGGTCA-3' (SEQ ID No. 8),
 5' -AGGTGA-CAGG-AGGTCA-3' (SEQ ID No. 9),
 5' -AGGTCA-CCAGG-AGGTCA-3' (SEQ ID No. 13),
 5' -AGGTGA-ACAGG-AGGTCA-3' (SEQ ID No. 14),

SEQ ID NOs:26, 28, 29, and the like.

These are especially preferred because they represent synthetic and/or invertebrate sequences which have not been observed in vertebrates, and thus are applicable to a wide
5 variety of reporter systems (i.e., the use of these response elements will not be limited due to any species preference based on the source of the sequence).

In accordance with yet another embodiment of the
10 present invention, there is provided a method to modulate, in an expression system, the transcription activation of a gene by a member of the steroid/thyroid superfamily of receptors in the presence of ligand therefor, and in the further presence of the ultraspiracle receptor, wherein the
15 expression of said gene is maintained under the control of a hormone response element, said method comprising:

exposing said system to compound(s) and/or
condition(s) which prevent association of said
member with the ultraspiracle receptor or
20 fragments thereof, in an amount effective to prevent said association.

Compound(s) and/or condition(s) which prevent
association of said member with the ultraspiracle receptor
25 include hormone-like compounds which act as agonists or antagonists for the ultraspiracle receptor, antibodies raised against the dimerization domain of the ultraspiracle receptor, antibodies raised against the dimerization domain of said member, antisense sequence(s) based on sequence(s)
30 complementary to known RNA encoding at least the dimerization domain of the ultraspiracle receptor, and the like. Amounts of agents effective to prevent such association will vary depending on the particular agents used and can be readily determined by those of skill in the
35 art; typically falling in the sub-nanomolar up to micromolar range.

In accordance with still another embodiment of the present invention, there is provided a method for modulating the expression of an exogenous gene in a subject containing:

5

(i) a DNA construct encoding said exogenous gene under the control of a steroid or steroid-like hormone response element; wherein said response element is not normally present in the cells of said subject,

10

(ii) a receptor which is not normally present in the cells of said subject, wherein said receptor, in the presence of its associated ligand and the ultraspiracle receptor, binds to said steroid or steroid-like hormone response element, and

15

(iii) the ultraspiracle receptor;

20

said method comprising administering to said subject an effective amount of said associated ligand; wherein said ligand is not normally present in the cells of said subject; and wherein said ligand is not toxic to said subject.

25

As employed herein, the term "exogenous" (or "foreign") genes refers to both wild type genes and therapeutic genes, which are introduced into the subject in the form of DNA or RNA, either natural or synthetic. The gene of interest can be introduced into target cells (for *in vitro* applications), or the gene of interest can be introduced directly into a subject, or indirectly introduced by the transfer of transformed cells into a subject.

30
35

"Wild type" genes are those that are native to cells of a particular type, but which may be undesirably overexpressed in these cells, or may not be expressed in these cells in biologically significant levels. Thus, for example, while a synthetic or natural gene coding for human insulin would be exogenous genetic material to a yeast cell (since yeast cells do not naturally contain insulin genes), a human insulin gene inserted into a human skin fibroblast cell would be a wild type gene with respect to that cell since human skin fibroblasts contain the genetic material encoding human insulin, although human skin fibroblasts do not express human insulin in biologically significant levels.

Wild type genes contemplated for use in the practice of the present invention include genes which encode a gene product:

the substantial absence of which leads to the occurrence of a non-normal state in said subject; or

a substantial excess of which leads to the occurrence of a non-normal state in said subject; and the like.

As employed herein, the phrase "therapeutic gene" refers to genes which impart a beneficial function to the host cell in which such gene is expressed. Therapeutic genes are those that are not naturally found in host cells. For example, a synthetic or natural gene coding for authentic human insulin would be therapeutic when inserted into a skin fibroblast cell so as to be expressed in a host human, where the host human is not otherwise capable of expressing functionally active human insulin in biologically significant levels.

Therapeutic genes contemplated for use in the practice of the present invention include genes which

encode a gene product:

which is toxic to the cells in which it is expressed; or

5 which imparts a beneficial property to said subject (e.g., disease resistance, etc); and the like.

Exogenous genetic material or genes useful in this embodiment of the present invention include genes that
10 encode secretory proteins that can be released from said cell; enzymes that can metabolize a substrate from a toxic form to a benign form, or from a benign form to a useful form; regulatory proteins; cell surface receptors; and the like. Such useful genes include, but are not limited to,
15 genes that encode blood clotting factors such as human factors VIII and IX; genes that encode hormones such as insulin, parathyroid hormone, luteinizing hormone releasing factor (LHRH), alpha and beta seminal inhibins, and human growth hormone; genes that encode proteins such as enzymes,
20 the absence of which leads to the occurrence of an abnormal state in said subject; genes encoding cytokines or lymphokines such as interferons, granulocytic macrophage colony stimulating factor (GM-CSF), colony stimulating factor-1 (CSF-1), tumor necrosis factor (TNF), and
25 erythropoietin (EPO); genes encoding inhibitor substances such as alpha₁-antitrypsin; genes encoding substances that function as drugs, e.g., genes encoding the diphtheria and cholera toxins; and the like.

30 Hormone response elements contemplated for use in this embodiment of the present invention involving modulating the expression of an exogenous gene in a subject include any sequence responsive to the above-described multimeric complex receptors, such as insect response
35 elements, and the like. See, for example, SEQ ID NOs: 26, 28 and 29.

Insect response elements contemplated for use in modulating the expression of an exogenous gene in a subject according to the present invention include, for example, ecdysone response elements, and the like.

5

Such response elements are operably linked to a suitable promoter for expression of the target gene product. As used herein, the term "promoter" refers to a specific nucleotide sequence recognized by RNA polymerase, the enzyme that initiates RNA synthesis. This sequence is the site at which transcription can be specifically initiated under proper conditions. When exogenous genes, operatively linked to a suitable promoter, are introduced into the cells of a suitable host, the exogenous genes are subject to expression control in the presence of hormone or hormone-like compounds not normally present in the host cells. Exemplary promoters include Δ MTV, Δ SV, Δ ADH promoters, and the like.

20

As employed herein, the phrase "receptor which is not normally present in the cells of said subject" refers to receptors which are not endogenous to the host in which the invention process is being carried out. Receptors which are not endogenous to the host include endogenous receptors modified so as to be non-responsive to ligands which are endogenous to the host in which the invention process is being carried out.

Receptor(s) not normally present in the cells of the subject and ultraspiracle receptor (or fragments thereof) can be provided to said subject by direct introduction of the proteins themselves, by introduction of RNA or DNA construct(s) encoding said receptors, by introduction of cells harboring genes encoding said receptor and/or response element, and the like. This can be accomplished in a variety of ways, e.g., by microinjection, retroviral infection, electroporation,

lipofection, and the like.

As employed herein, the phrase "associated ligand" refers to a substance or compound which, inside a cell, binds to the receptor protein, thereby creating a ligand/receptor complex, which in turn can bind to an appropriate hormone response element. An associated ligand therefore is a compound which acts to modulate gene transcription for a gene maintained under the control of a hormone response element, and includes compounds such as hormones, growth substances, non-hormone substances that regulate growth, and the like. Ligands include steroid or steroid-like hormones, retinoids, thyroid hormones, pharmaceutically active compounds, and the like. Individual ligands may have the ability to bind to multiple receptors.

In accordance with a still further embodiment of the present invention, there is provided a method of inducing the expression of an exogenous gene in a subject containing:

- (i) a DNA construct encoding an exogenous gene product under the control of a hormone response element; wherein said response element is not normally present in the cells of said subject,
- (ii) DNA encoding a receptor which is not normally present in the cells of said subject, under the control of an inducible promoter; wherein said receptor, in the presence of its associated ligand and the ultraspiracle receptor, binds to said hormone response element,
- (iii) the ultraspiracle receptor, and
- (iv) the associated ligand for said receptor;

said method comprising subjecting a subject to conditions suitable to induce expression of said receptor.

In accordance with yet another embodiment of the present invention, there is provided a method of inducing expression of an exogenous gene product in a subject containing a DNA construct encoding said product under the control of a hormone response element; wherein said response element is not normally present in the cells of said subject, said method comprising introducing into said subject:

a receptor which is not normally present in the cells of said subject; wherein said receptor, in combination with its associated ligand and the ultraspiracle receptor, binds to a hormone response element, activating transcription therefrom,

the ultraspiracle receptor, and
the associated ligand for said receptor which is not normally present in the cells of said subject.

In accordance with this embodiment of the present invention, receptor can be provided directly to said subject as the protein, or indirectly by administering to said subject a second DNA construct encoding said receptor, or by administering to said subject cells harboring such constructs. When introduced as part of a second DNA construct, expression of said exogenous gene product and the receptor is preferably maintained under the control of a tissue specific promoter.

In accordance with a further embodiment of the present invention, there is provided a method for the expression of recombinant products detrimental to a host organism, said method comprising:

transforming suitable host cells with:

(i) a construct comprising a sequence encoding said recombinant product under the control of a hormone response element;

5 wherein said response element is not normally present in the cells of said host, and

(ii) DNA encoding a receptor not normally present in said host cells;

10 growing said host cells to the desired level in the substantial absence of hormone(s) which, in combination with said receptor not normally present in the cells of said host and ultraspiracle receptor, is capable of binding to said hormone response element, and

15 inducing expression of said recombinant product by introducing into said host cells the ultraspiracle receptor and hormone(s) which, in combination with said receptor not normally present in the cells of said host, bind to said response element.

20 In one aspect of this embodiment of the invention, wherein host is employed as an expression system for the production of a recombinant product which is toxic to the host, recombinant product is induced only after cell
25 growth (as opposed to protein expression conditions) has produced a desired density of cell mass. Thus, the desired level of growth in accordance with this embodiment is a level which produces a high cell density, and thereafter expression of product is induced. Conditions suitable for
30 cell growth (and for protein expression, when desired) can be readily determined by those of skill in the art.

In another aspect of this embodiment of the present invention, wherein the host harbors a DNA construct
35 as described above, expression of the construct to produce the detrimental product causes ablation of the cells harboring said construct. In this aspect, the desired

level of growth is that level appropriate to ensure the desired distribution of cells harboring the inducible construct. Thus, expression will be induced when it is desired to ablate such cells.

5

As used herein, "ablation" refers to removing or eliminating specific cell types in a culture of a cell population, or in a transgenic animal host by means of a DNA construct that encodes a protein whose presence is not per se toxic to the cells, but which can confer upon the cells a toxic potential due to the ability of the protein to control the expression of substances that are or will become toxic to the cells.

The elimination of specific cell-type(s) or specific cell line(s) in accordance with one aspect of the present invention produces a cell population which is substantially free of cells which are not normally present in the wild-type cell population. The elimination of specific cell-type(s) or specific cell line(s), in accordance with another aspect of the present invention, produces a defined altered state in the treated subject.

Cell(s) or cell line(s) contemplated to be eliminated in accordance with the present invention can be a cell or cell line capable of providing a desirable component to a cell population, as an exogenous gene product; wherein the ability to eliminate said cell or cell line from said cell population is desired, e.g., once said population achieves the ability to produce sufficient quantities of such component as an endogenous gene product; or, the cell line to be eliminated can be a diseased cell line or a cell line predisposed to a disease state.

Normal cell(s) or cell line(s) contemplated to be eliminated in accordance with the present invention are cell(s) or cell line(s), the elimination of which would

result in the creation of a defined altered state in the cell population.

In accordance with a still further embodiment of the present invention, there is provided a method to distinguish the physiological effect of a first hormone receptor in a host from other hormone receptors in said host which respond to the same ligand, said method comprising:

replacing the ligand binding domain of said first receptor with a ligand binding domain from an exogenous receptor to produce a chimeric receptor maintained under the control of a tissue specific promoter;

wherein said exogenous receptor and the ligand to which the exogenous receptor responds are not normally present in said host; and

wherein said exogenous receptor, in the presence of its associated ligand, binds to a hormone response element, thereby activating said response element, and thereafter

monitoring the production of product(s) whose expression is controlled by said first hormone receptor when said host is exposed to ultraspiracle receptor and ligand to which said exogenous receptor responds.

In accordance with yet another embodiment of the present invention, there is provided a method to render a mammalian hormone receptor uniquely responsive to a ligand not endogenous to host(s) in which said receptor is normally found, said method comprising:

replacing the ligand binding domain of said receptor with a ligand binding domain from a second receptor;

wherein said second receptor is not normally present in said host; and wherein the ligand to which the second receptor responds is not normally present in said host.

In accordance with a still further embodiment of the present invention, there is provided a method to determine the ligand(s) to which orphan receptor(s) responds, said method comprising:

5 monitoring a host cell containing a reporter construct and a hybrid receptor for expression of product(s) of said reporter construct upon contacting said cell with potential ligands for said orphan receptor and the ultraspiracle receptor;

10 wherein said reporter construct comprises a gene encoding a reporter molecule, operatively linked for transcription to a steroid or steroid-like hormone response element; wherein said response element is not normally present in the cells of said host;

15 wherein said hybrid receptor comprises:

20 the N-terminal domain and DNA binding domain of a member of the steroid/thyroid superfamily of receptors, wherein said member is not normally present in the host cells, and wherein said member, in the presence of its associated ligand, binds said response element, activating transcription therefrom, and

25 the ligand binding domain of said orphan receptor.

In accordance with yet another embodiment of the present invention, there is provided an isolated DNA which
30 encodes the ultraspiracle receptor, as described above as well as functional fragments thereof. The complete nucleotide sequence for the ultraspiracle receptor is presented in SEQ ID NO:1 [see also, Oro et al., in Nature 347: 298-301 (1990)]. Also contemplated within the scope
35 of the present invention are sequences encoding polypeptides comprising a DNA binding domain with substantially the same sequence as that of amino acids

104 - 169 shown in SEQ ID NO:2 (i.e., the DNA binding domain of the ultraspiracle receptor). Also contemplated are sequences encoding polypeptides having substantially the same sequence as that of amino acids 1 - 513 shown in
5 SEQ ID NO:2. Also contemplated are sequences having substantially the same nucleotide sequence as nucleotides 163 - 1704 shown in SEQ ID NO:1. As employed herein, the term "substantially the same as" refers to DNA having at least about 70% homology with respect to the nucleotide
10 sequence of the DNA fragment with which subject DNA is being compared. Preferably, DNA "substantially the same as" a comparative DNA will be at least about 80% homologous to the comparative nucleotide sequence; with greater than about 90% homology being especially preferred. Also
15 contemplated are DNAs able to hybridize to the above-described sequences, and having substantially the same functional properties thereof. A presently preferred DNA of the invention is the *EcoRI* fragment of vector pXR2C8 [see Oro, et al., supra].

20 DNA of the invention can optionally be incorporated into expression vector(s) operative in a cell in culture to make the ultraspiracle receptor (or functional fragments thereof) by expression of said DNA in
25 said cell. For example, the transcription of DNA can be controlled by the *Drosophila melanogaster* actin 5C promoter. Host cells which can employed for expression of said DNA include *Drosophila melanogaster* Schneider line 2 cells, Kc cells, and the like.

30 The invention will now be described in greater detail by reference to the following non-limiting examples.

EXAMPLESExample IPlasmids

CMX-EcR was constructed by digesting pActEcR plasmid [Koelle et al., Cell Vol. 67:59-77 (1991)] with HindIII. The resulting HindIII fragment, which contains the EcR coding region, was then inserted into CMXPL1, a derivative of CMX expression vector [Umesono et al. Cell Vol. 65:1255-1266 (1991)]. Expression plasmid CMX-usp was made by inserting the EcoRI fragment from the cDNA clone [Oro et al., Nature Vol. 347:298-301 (1990)] which contains all the usp coding region into CMXPL1 vector. Δ MTV-EcRE5-CAT was constructed by ligation of an EcRE-containing oligonucleotide (SEQ ID NO: 22):

5'-AGCTCGATGG ACAAGTGCAT TGAACCCTTG A
GCTACC TGTTCACGTA ACTTGGGAAC TTCGA

into HindIII-cleaved Δ MTV-CAT [Hollenberg and Evans, Cell Vol. 55:899-906 (1988)]. Restriction analysis and sequencing of the construct indicated that it contains 5 copies of this oligonucleotide.

GEcR was constructed by ligation of a NotI/BamHI fragment containing the DNA and hormone binding domains of a modified EcR cDNA, EcRnx, in place of the DNA and hormone binding domains of the similarly modified glucocorticoid receptor expression construct pRShGRnx [Giguère et al., Nature Vol. 330:624-629 (1987)]. The modified receptor cDNA was constructed using the site-directed mutagenesis procedure of Kunkel, T.A., Proc. Natl. Acad. Sci. USA Vol. 82:448-492 (1985) to insert NotI (employing SEQ ID NO:23 as the oligonucleotide template) and XhoI (employing SEQ ID NO:24 as the oligonucleotide template) sites immediately flanking the DNA binding domain. SEQ ID NO:23 is:

5'-CCTGCGCCAC GGCGCCGCC GGAGCTGTG CCTG; and

SEQ ID NO:24 is:

5'-GTGGGTATG CGCCTCGAGT GCGTCGTCCC.

This mutagenesis procedure results in conversion of amino acids 258-260 from ValGlnGlu to ArgProPro and amino acid
5 331 from Pro to Leu.

Example II

Preparation of receptor protein, cell extracts and gel mobility shift assay

10

To generate protein in vitro, suitable plasmids for human (h)RAR α , hTRB, hVDR, rat PPAR, *Drosophila* (d)usp and dEcR were linearized with restriction enzyme 3' of the termination codon. The linearized templates were used for
15 in vitro transcription and then translation using rabbit reticulocyte lysate according to manufacturer's instruction (Promega). *Drosophila* embryo extract was a gift from Dr. J. Kadonaga and prepared as described by Zoeller et al., in Genes Dev., Vol. 2:68-81 (1988). Schneider cell extracts
20 were prepared following the procedures in Damm et al., Nature Vol. 339:593-597 (1989) and Umesono et al. (1991), supra. The extraction buffer contained 0.4 M KCl in 20 mM HEPES pH 7.5, 20% glycerol, 2 mM DTT and 1 mM PMSF.

25 For gel mobility shift assay, proteins were incubated with binding buffer, which contained 100 mM KCl, 7.5% glycerol, 20 mM HEPES pH 7.5, 2 mM DTT and 0.1% NP-40, on ice for 20 minutes in the presence of 2 μ g of nonspecific competitor poly dI-dC and other oligo
30 competitors. Then approximately 1 ng of 32 P-dCTP probe, which was labelled to specific activity about $1-5 \times 10^8$ cpm/ μ g by fill-in reaction with Klenow fragments, was added to the reaction and incubated at room temperature for 20 minutes. Antiserum or preimmune serum was added 10 minutes
35 after the probe was added. The reaction was then loaded into 5% non-denaturing polyacrylamide gel in 0.5 X TBE running buffer [1 X TBE comprises 0.089 M Tris borate,

0.089 M boric acid and 0.002 M EDTA]. After electrophoresis, the gel was dried for autoradiography.

EXAMPLE III

5 Preparation of usp antiserum

Primers were designed to amplify the usp coding region which either covered the entire N-terminal and DNA binding domain (from amino acid 1 to 210; GST-uspN) or the
10 complete coding region (GST-usp) by polymerase chain reaction (PCR). The amplified fragments were subcloned into PGEX2T vector (Pharmacia) for expression in bacteria. The expression of GST fusion protein was performed according to the manufacturer's directions (Pharmacia).

15 The fusion protein GST-uspN was prepared and fractionated on SDS polyacrylamide gel and the band corresponding to the fusion protein was excised. The gel slice was fragmented and used to immunize the rabbit at
20 three week intervals. The rabbit sera were collected and tested by Western Blot for the ability to recognize usp protein. The positive sera were further purified by the procedure described in Vaughan et al., Met. in Enzymol. (Academic Press Vol. 168:588-617 (1989) with slight
25 modification. Briefly, full length GST-usp fusion protein and GST protein were purified using Glutathione Sepharose 4B (Pharmacia). The purified proteins were individually coupled to affi-gel 10 according to the manufacturer's protocol (Biorad).

30 To affinity purify the antibody, the crude antiserum was first incubated with GST-coupled affi-gel for 2.5 hours at 4°C with gentle rocking. The unbound fraction was separated from the beads by centrifugation. The
35 supernatant was then incubated with full length GST-usp coupled affi-gel overnight at 4°C with gentle rocking. The contents were then packed into column and washed with 50 mM

HEPES pH 7.5 supplemented with 0.5 M NaCl. The bound antibodies were eluted by 100 mM glycine. The eluted fractions were neutralized with 1 M Tris pH 8 and pooled; then dialyzed against PBS buffer which contained 0.02% of sodium azide. The purified antiserum was concentrated by Centricon 30 (Amicon) before it was stored. This purified antibody is very specific as it does not cross react with RXRs. It also does not react with other closely related fly nuclear receptors including seven up (svp) type I, II [Mlodzik et al., Cell 60:211-224 (1990)].

Example IV Cotransfection assay

Transfection was performed with calcium-phosphate precipitation method as described previously [Umesono et al., Nature 336:262-264 (1989)]. CV1 monkey kidney cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% calf bovine serum. The cells were transfected for 8-9 hours and then the DNA precipitates were washed away and replaced with fresh medium with 10% charcoal-resin double stripped fetal bovine serum. 20-hydroxy-ecdysone (Sigma; 10 mg/ml in ethanol), or ethanol alone was then given to the cells. 24-28 hours later, the cells were harvested. Beta-galactosidase (β Gal) activity was measured and a normalized amount of extract was used for CAT assay (Umesono et al. (1989) supra). The following amount of plasmid DNA was included in the 10 cm plate transfection: 250 ng each of CMX-EcR and RSV-GEcR; 500 ng of CMX-usp; 5 μ g Δ MTV-EcRE₅-CTA; 5 μ g of β Gal internal control plasmid CH111 (a derivative of CH110, Promega). The amount of CMX plasmid was kept constant in each transfection by adding CMX-luciferase. PGEM4 was added to bring the total amount of plasmid DNA to 15 μ g per plate.

EXAMPLE V

usp is the Drosophila nuclear factor that can
enhance RAR DNA binding activity

5 It has previously been shown that the DNA binding
activity of bacterially expressed RAR can be enhanced by
adding cell extracts to the binding reaction [Yang et al.,
Proc. Natl. Acad. Sci. USA 88:3559-3563 (1991)]. Extracts
prepared from both mammalian cells and the *Drosophila*
10 Schneider cell line 2 (S2) had similar effects [Yang et
al., supra]. The presence of this enhancing activity in
Drosophila cells indicates that a general conserved
mechanism may be utilized in both mammals and *Drosophila* to
regulate DNA binding activity of receptors like RAR. To
15 address this question, experiments were set up to
characterize this *Drosophila* nuclear activity in S2 cell
extracts and in embryo extracts.

 In gel mobility shift assays using a ³²P-labelled
20 natural RAR response element - BRARE [see SEQ ID NO:15, see
also de Thé et al., in Nature Vol. 343:177-180 (1990); and
Sucov et al., in Proc. Natl. Acad. Sci. USA Vol. 87:5392-
5398 (1990)] as the probe, in vitro translated RAR α was
incubated with probe under binding conditions either alone
25 or with 2 μ g of S2 extracts or embryo extracts. In vitro
translated RAR α , by itself, did not bind with appreciable
affinity. For mammalian extracts [Glass et al., Cell Vol.
63:729-738 (1990)], incubating the RAR α with either S2 or
Drosophila embryo extracts dramatically enhanced DNA
30 binding activity, while cell extract alone did not show
similar binding activity.

 Two clues suggested the possibility that the
observed enhancing activity might be the ultraspiracle
35 receptor (usp). First, RXR, the putative vertebrate
homologue of usp, has been shown to enhance RAR DNA binding
[Yu et al., Cell Vol. 67:1251-1266 (1991); Kliewer et al.,

Nature Vol. 355:446-449 (1992); Leid et al., Cell Vol. 68:377-395 (1992)]. Second, usp protein has been found to be present in both S2 and embryo extracts with relative abundance. Based on these observations, it was investigated whether usp is the *Drosophila* nuclear activity that can interact with RAR. An affinity purified antibody against usp, prepared as described in Example III, was added to the mobility shift reaction. The affinity purified antibody supershifted the majority of the protein DNA complex while preimmune serum had no effect in the mobility pattern. By incubating with higher concentration of usp antibody, essentially all the binding complex was supershifted. These results indicate that the activity present in both types of fly extracts can be attributed to usp protein and that usp is likely the major factor in the extract which interacts with RAR.

To further show that usp is indeed the *Drosophila* component involved in the RAR interactions, usp protein was in vitro translated in the rabbit reticulocyte lysate (see Example II for procedure employed) and tested whether in vitro translated usp can mimic the fly extracts' activity to interact with RAR α . Neither in vitro translated usp alone, nor RAR α alone, bound to a β RARE probe. However, when the two proteins were incubated together, a prominent retarded complex appeared. This complex comigrated with the complex detected in the RAR and cell extract mixing experiments. The presence of both usp and RAR protein in this protein/DNA complex was demonstrated by the antibodies raised against usp and RAR α . Either the affinity purified usp antibody, or the RAR α , specifically affected the protein/DNA complex, while preimmune sera had no effect. This complex likely represents an RAR/usp heterodimer, as its mobility is similar to the RXR/RAR complex which has been proposed to be a heterodimeric species [Yu et al., supra; Kliever et al., supra; Leid et al., supra]. Thus it is concluded that usp is the *Drosophila* nuclear activity

which can interact with RAR in binding to specific RARE via the formation of a putative heterodimer.

Example VI

5 usp can heterodimerize with several members of the mammalian nuclear receptor family

10 The finding that usp is able to heterodimerize with RAR suggested that it would be appropriate to check whether this interaction reflected a general ability of usp to form heterodimers with other members of the steroid/thyroid superfamily. Using in vitro translated usp protein, interaction of usp with three mammalian nuclear receptors (TR β , VDR and PPAR) was tested in gel mobility shift assays with the appropriate response element for each of the three receptors as the probes. Response elements used were as follows:

	Response Element	Abbreviation	Sequence	SEQ IN NO:
20	AOX-PPARE	(DR1) ¹	AGGACA A AGGTCA	25
	SSP1-VDRE	(DR3) ²	GGTTCA CGA GGTTCA	7
	MLV-TRE	(DR4) ³	GGGTCA TTTC AGGTCC	12
	BRARE	(DR5) ⁴	GGTTCA CCGAA AGTTCA	15

- 25 ¹Kliewer et al., submitted to Nature, entitled "9-Cis Retinoic Acid and Peroxisome Proliferator Signalling Pathways Converge Through RXR α -PPAR Interactions"
- ²Noda et al., Proc. Natl. Acad. Sci. USA 87:9995-9999 (1990)
- ³Sap et al., Nature 340:242-244 (1989)
- 30 ⁴Sucov et al., supra.

For a review providing further discussion with respect to these response elements, see Umesono et al., 1991, supra.

35 With any of the receptors alone (prepared by in vitro translation from cDNA clones) there was very little or no binding to the test probes. However, when they were incubated with usp, a dramatic increase in DNA binding activity could be detected. In a usp dependent fashion,

40 TR β bound to a natural TR response element (MLV-TRE) and VDR/usp bound to SSP1-VDRE, a natural VDR response element. The usp and PPAR interaction was tested on a PPARE derived

from the acyl CoA oxidase promoter (AOX, Kliewer et al., submitted, supra, and references cited therein). PPAR/usp complex bound to AOX-PPARE with high affinity. The usp antibody again showed the presence of usp in those
 5 complexes by shifting the retarded bands in all three combinations, whereas preimmune serum did not affect the binding pattern. Oligonucleotide competition assay demonstrated that the usp dependent heterodimers all showed correct response element specificity. Therefore, by
 10 interacting with usp to form heterodimer, all four mammalian receptors tested achieved high affinity DNA binding to their cognate response elements. It can be concluded, therefore, that the ability of usp to interact with other receptors to form heterodimers is a
 15 characteristic feature of usp, and that receptor heterodimer formation, as exemplified by RXR and usp, is conserved between vertebrates and invertebrates.

Example VII

Ecdysone receptor and usp can heterodimerize to form a high affinity DNA binding complex

If the substitution of usp for RXR in heterodimerization with RAR and other mammalian receptors
 25 represents a conserved feature of mammalian and *Drosophila* receptors, it can be speculated that there might be one or more *Drosophila* activities which can interact with usp. The ligand binding domain has been shown to contain the dimerization domain for some nuclear receptors [Forman et
 30 al., Mol. Endocrinol. Vol. 3:1610-1626 (1989); Fawell et al., Cell 60:953-962 (1990)] and it is also essential for interaction between RAR and nuclear factors including RXR [Glass et al., supra; Kliewer et al. supra]. Sequence comparisons reveal that, with respect to the ligand binding
 35 domain, all RXR heterodimer partners, including RAR, TR and VDR, are much more similar to one another than to other receptors, particularly RXR. Among the *Drosophila* receptor

members, ecdysone receptor (EcR) is one of the receptors which shows strong homology to RAR, VDR and TR within this region. This homology suggests EcR may have an evolutionarily conserved domain that, like RAR, VDR and TR, allows EcR to interact with usp.

To test the potential interaction between usp and EcR, experiments were carried out to determine whether usp is part of the defined EcR DNA binding activity present in ecdysone responsive Schneider 2 cells [Koelle et al. Cell 67:59-77 (1991)]. As shown by Koelle et al., in a gel mobility shift assay using a natural ecdysone response element derived from hsp27 promoter (³²P-labelled hsp27-EcRE, Riddihough and Pelham, EMBO J. Vol. 6:3729-3734 (1987)) as the probe, one specific major complex could be detected in the S2 extract. This complex can be competed away by specific cold oligonucleotide but not by the unrelated oligonucleotide competitor GREpal, a glucocorticoid response element. To determine whether usp is present in this EcRE binding complex, affinity purified usp antibody was added to the reaction. usp antibody can supershift the specific EcRE binding complex from the S2 extract but not the lower minor complex, which was much less sensitive to the specific cold oligonucleotide competition. Preimmune serum had no effect on the upper major complex but it disrupted the lower minor complex. Antibody against RXR α and RAR γ did not affect the specific complex. Therefore, these data demonstrate that usp is part of the EcRE DNA binding complex present in S2 cells, strongly suggesting an interaction between EcR and usp.

The EcR and usp interaction was also tested under more defined conditions. In vitro translated EcR and usp were prepared and their interaction was assayed by gel mobility shift assays. Using the same hsp27-EcRE as the probe, usp did not bind to this element by itself. EcR also failed to bind to hsp27-EcRE, in contrast to the EcRE

binding activity in S2 cells. To test whether usp can complement ECR DNA binding, as it does with mammalian receptors, both usp and ECR were co-incubated in the reaction. In the presence of both receptors, a novel high affinity DNA binding complex appeared. Usp antibody, but not preimmune serum, can supershift the complex, demonstrating that usp is part of the complex. This complex is proposed to be a heterodimeric species, which is consistent with the observation of other usp heterodimers. These data demonstrate that ECR binding to ecdysone response element (hsp27-EcRE) depends upon usp and are consistent with the existence of a functionally significant ECR/usp complex.

Example VIII

DNA binding activity of ECR/usp heterodimer is correlated with the ecdysone responsiveness in vivo

To establish that the ECR/usp heterodimer is physiologically relevant, it was set out to determine whether the DNA binding properties of ECR/usp heterodimer can be correlated with ecdysone responsiveness in vivo. This was done by testing ECR/usp heterodimer binding to several wild type and mutant EcREs characterized by their differential ability to mediate the ecdysone responsiveness in cultured cells (for review see Cherbas et al., Genes Dev. Vol. 5:120-131 (1991)). The response elements used in this study are set forth below. The position and the orientation of ERE-like half sites (AGGTCA-like) are marked by arrows. For example, the palindromic motif in hsp27-EcRE is indicated by arrows arranged as → ←. The mutated nucleotides in 11N and 15N-EcRE are in small letters. The arrow in 11N-EcRE covers where the remaining palindromic motif extends. In Eip28/29-EcRE, which is named as dis*-Eip28/29 in Cherbas et al., supra, the half site which can constitute a highly degenerated palindrome is marked with a wavy, broken line. Note that two ERE half sites are

present in the configuration of direct repeats spaced by three nucleotides in Eip28/29-EcRE. The ability of individual response elements to mediate ecdysone response in cultured cells (summarized from Cherbas et al., supra)
5 and to serve as high affinity binding site for EcR/usp complex are summarized to the right of the sequences.

2

An EcRE derived from the *Drosophila* Eip28/29 gene has been shown to mediate ecdysone response in cultured cells [Cherbas et al., supra]. In contrast to the hsp27-EcRE palindrome, the Eip28/29-EcRE is a composite element containing a direct repeat and a highly degenerated palindromic motif. The ability of EcR/usp complex to recognize this EcRE was examined. This element can effectively compete the EcR/usp binding to hsp27-EcRE. This competition is as effective as that of the hsp27-EcRE itself, demonstrating that the Eip28/29-EcRE is also a high affinity binding site for EcR/usp complex. In contrast, an unrelated competitor (GREpal) had no effect on the DNA binding. The high affinity binding by the EcR/usp complex parallels the ability the Eip28/29-EcRE to mediate ecdysone response in culture cells.

In contrast to the high affinity binding referred to above, a mutant hsp27-EcRE (referred as 11-N-hsp by Cherbas et al., supra, wherein the two nucleotides at the ends of the palindrome and the flanking sequence were changed), failed to serve as a high affinity binding site for the EcR/usp. This oligonucleotide did not compete the specific binding of EcR/usp to hsp27-EcRE, which was consistent with the observation that this mutated EcRE failed to confer ecdysone responsiveness to a heterologous promoter in transfection assay (Cherbas et al., supra). However, a back mutation which regenerated the palindrome motif (15-N-hsp) led to recovery of the ecdysone responsiveness and effective competition for the EcR/usp binding to the wild type hsp27-EcRE. Therefore, the ability of a specific EcRE motif to mediate the ecdysone response in vivo correlated well with its ability to serve as high affinity binding site for EcR/usp complex. These data suggest that the EcR/usp complex can mediate the ecdysone response in vivo.

Example IXusp is present in the embryonic EcRE binding activity

Phenotypic analysis of usp reveals that it is
5 required at a number of developmental events which are
correlated with known or potential ecdysone-regulated
processes. For example, usp is found to be a necessary
component for the completion of embryogenesis [Oro et al.,
"The *Drosophila* retinoid X receptor homolog ultraspiracle
10 functions in both female reproduction and eye
morphogenesis", Development, in press (1992)]. The
presence of the ecdysone pulse [Richards, G., Mol. and
Cell. Endocrinol. Vol. 21:181-197 (1981)] as well as the
EcR protein (Koelle et al., supra) during embryogenesis
15 indicates that EcR is also required during embryonic
development.

Based on the coexpression and functional
requirement of both activities, it was next tested whether
20 EcR and usp can interact during this developmental stage.
To this end, the EcRE binding activities in the embryo
extract were determined by mobility shift assay using 5-10
µg of embryo extract and ³²P-labelled hsp27-EcRE as the
probe. Specific EcRE binding complexes can be detected, as
25 demonstrated by specific oligonucleotide and unrelated
oligonucleotide competition. Indeed, usp is present in
those complexes, as usp antibody was able to supershift
those complexes. Preimmune serum did not alter the
mobility pattern, although a slightly enhanced overall DNA
30 binding was observed. The detection of multiple EcRE
binding complexes is consistent with the existence of
multiple forms of EcR protein which have been reported
(Koelle et al., supra). The identities of these complexes
as EcR complexes were supported by the fact that the upper
35 complex comigrated with the EcR complex present in the S2
extract and that the DNA binding specificity of these
complexes as assayed by oligonucleotide competition was

indistinguishable from the ECR/usp complex prepared in vitro.

Based on these data, it can be concluded that the embryonic ECRE binding complexes contain usp. These data suggest an interaction between endogenous usp and ECR in the *Drosophila* embryo, where both activities are required for embryonic development.

Example X

usp is required for ecdysone responsiveness in heterologous cultured cells

The in vitro DNA binding data suggests that usp is required for ECR high affinity DNA binding. The detection of ECR/usp heterodimeric DNA binding complex from embryo implies that they may interact in vivo. To determine whether usp and ECR can functionally interact in vivo, cotransfection experiments were set up to assay if usp is required for ECR to exert an ecdysone response in cultured cells. Mammalian cells were chosen as the heterologous system because they do not contain endogenous ECR and usp background.

Ecdysone response in CV1 cells was determined by using an ecdysone-responsive reporter gene (Δ MTV-ECRE₅-CAT), which contains the same core hsp27-ECRE motif tested in DNA binding assay described earlier. The chloramphenicol acetyl transferase (CAT) activity induced by ecdysone was measured in the presence of different combinations of transfected ECR and usp expression vectors. CAT activity is expressed in Figure 2 as the percentage of conversion which is normalized against the level in ECR alone at the presence of ecdysone assigned as one (column 1, shaded rectangle). The final concentration of 20-hydroxy-ecdysone (Sigma) is 40 μ M. Columns 1 and 2 show that transfection with ECR alone (column 1) or usp alone (Column 2) does not

respond to 20-OH-ecdysone treatment. Cotransfection of EcR and usp together is shown in column 3 and the induction of CAT activity could be observed by about 3 fold. The requirement of EcRE for induction is demonstrated by using
 5 the parental Δ MTV-CAT as reporter. This construct does not respond to ecdysone (column 4).

As shown in Figure 2A, transfection of EcR alone failed to confer responsiveness to 20-hydroxy-ecdysone,
 10 consistent with the idea that EcR by itself cannot mediate ecdysone response. To test whether usp can complement the EcR activity as it did in the DNA binding assay, usp expression vector was cotransfected with EcR into CV1 cells. Cotransfection of usp with EcR indeed was able to
 15 confer a significant response to 20-OH-ecdysone (over 3 fold, Figure 2A). This induction was strictly dependent on both EcR and EcRE, as transfection with usp expression plasmid alone or a reporter construct without EcRE (Δ MTV-CAT) did not result in ecdysone responsiveness (Figure 2A).
 20 The level of induction by EcR and usp in CV1 cells is significant but somewhat lower than expected compared with the interaction in DNA binding assay.

To address the possibility that EcR may not
 25 function properly in mammalian cells, the N-terminal domain of the glucocorticoid receptor (GR) was fused to the EcR DNA binding domain and ligand binding domain to create the construct GEcR (see Example 1). The presence of the GR N-terminal domain, which contains a transactivating domain
 30 [Hollenberg and Evans, supra], should increase the transcriptional potency and provide an optimal translation signal for *Drosophila* EcR protein to function properly in the mammalian cells. This construct retained the ability to interact with usp in DNA binding assay. Since usp did
 35 not interact with GR in either DNA binding or in transfection assay, it is clear that GR N-terminal fusion should not affect the basic property of EcR to interact

with usp. A similar GR fusion protein with TR has been shown to behave like wild type TR except that it is a more potent transactivator [Thompson and Evans, Proc. Natl. Acad. Sci. USA Vol. 86:3494-3498 (1989)]. Therefore this
5 system should increase the sensitivity of a functional interaction between usp and EcR while faithfully retaining the basic property of EcR.

As shown in Figure 2B, expression plasmid of GEcR
10 was transfected into CV1 cells alone, or with usp expression plasmid. The conversion of CAT was normalized as described for panel A. Note that the scales of the CAT conversion in Figure 2, panels A and B are different. Similar to the results obtained with wild type EcR,
15 transfection of GEcR alone failed to confer ecdysone response. However, when cotransfected with the usp expression plasmid, the 20-OH-ecdysone treatment induced CAT activity by 8-10 fold (Figure 2B). This induction was also dependent on the presence of the EcRE in the reporter
20 constructs. Thus, the GEcR mediated ecdysone response is similar to EcR except the signal level is higher (compare Figure 2A and 2B). In conclusion, the presence of usp appears to be essential for EcR and GEcR to exert an ecdysone response in CV1 cells. These data demonstrate
25 that EcR and usp can interact in vivo and constitute a functional ecdysone response in a heterologous cell line.

While the invention has been described in detail with reference to certain preferred embodiments thereof, it
30 will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.

SEQUENCE LISTING

SEQ ID NO:1

GGACACGGTG GCGTTGGCAA AGTGAAACCC CAACAGAGAG GCGAAAGCGA GCCAAGACAC	60
ACCACATACA CACGAAGAGA ACCAGCAAGA AGAAACCGGT AGGCGGAGGA GGCGCTGCCC	120
CCAGTTCCTC CAATATACCC AGCACCACAT CACAAGCCCA GG ATG GAC AAC TGC	174
Met Asp Asn Cys	
1	
GAC CAG GAC GCC AGC TTT CGG CTG AGC CAC ATC AAG GAG GAG GTC AAG	222
Asp Gln Asp Ala Ser Phe Arg Leu Ser His Ile Lys Glu Glu Val Lys	
5 10 15 20	
CCG GAC ATC TCG CAG CTG AAC GAC AGC AAC AAC AGC AGC TTT TCG CCC	270
Pro Asp Ile Ser Gln Leu Asn Asp Ser Asn Asn Ser Ser Phe Ser Pro	
25 30 35	
AAG GCC GAG AGT CCC GTG CCC TTC ATG CAG GCC ATG TCC ATG GTC CAC	318
Lys Ala Glu Ser Pro Val Pro Phe Met Gln Ala Met Ser Met Val His	
40 45 50	
GTG CTG CCC GGC TCC AAC TCC GCC AGC TCC AAC AAC AAC AGC GCT GGA	366
Val Leu Pro Gly Ser Asn Ser Ala Ser Ser Asn Asn Asn Ser Ala Gly	
55 60 65	
GAT GCC CAA ATG GCG CAG GCG CCC AAT TCG GCT GGA GGC TCT GCC GCC	414
Asp Ala Gln Met Ala Gln Ala Pro Asn Ser Ala Gly Gly Ser Ala Ala	
70 75 80	
GCT GCA GTC CAG CAG CAG TAT CCG CCT AAC CAT CCG CTG AGC GGC AGC	462
Ala Ala Val Gln Gln Gln Tyr Pro Pro Asn His Pro Leu Ser Gly Ser	
85 90 95 100	
AAG CAC CTC TGC TCT ATT TGC GGG GAT CGG GCC AGT GGC AAG CAC TAC	510
Lys His Leu Cys Ser Ile Cys Gly Asp Arg Ala Ser Gly Lys His Tyr	
105 110 115	
GGC GTG TAC AGC TGT GAG GGC TGC AAG GGC TTC TTT AAA CGC ACA GTG	558
Gly Val Tyr Ser Cys Glu Gly Cys Lys Gly Phe Phe Lys Arg Thr Val	
120 125 130	
CGC AAG GAT CTC ACA TAC GCT TGC AGG GAG AAC CGC AAC TGC ATC ATA	606
Arg Lys Asp Leu Thr Tyr Ala Cys Arg Glu Asn Arg Asn Cys Ile Ile	
135 140 145	
GAC AAG CGG CAG AGG AAC CGC TGC CAG TAC TGC CGC TAC CAG AAG TGC	654
Asp Lys Arg Gln Arg Asn Arg Cys Gln Tyr Cys Arg Tyr Gln Lys Cys	
150 155 160	
CTA ACC TGC GGC ATG AAG CGC GAA GCG GTC CAG GAG GAG CGT CAA CGC	702
Leu Thr Cys Gly Met Lys Arg Glu Ala Val Gln Glu Glu Arg Gln Arg	
165 170 175 180	
GGC GCC CGC AAT GCG GCG GGT AGG CTC AGC GCC AGC GGA GGC GGC AGT	750
Gly Ala Arg Asn Ala Ala Gly Arg Leu Ser Ala Ser Gly Gly Gly Ser	
185 190 195	
AGC GGT CCA GGT TCG GTA GGC GGA TCC AGC TCT CAA GGC GGA GGA GGA	798
Ser Gly Pro Gly Ser Val Gly Gly Ser Ser Ser Gln Gly Gly Gly Gly	
200 205 210	

00526299.031500

GGA Gly	GGC Gly	GGC Gly 215	GTT Val	TCT Ser	TCT Gly	GGA Gly	ATG Met 220	GGC Gly	AGC Ser	GGC Gly	AAC Asn	GGT Gly 225	TCT Ser	GAT Asp	GAC Asp	846
TTC Phe	ATG Met 230	ACC Thr	AAT Asn	AGC Ser	GTG Val	TCC Ser 235	AGG Arg	GAT Asp	TTC Phe	TCG Ser	ATC Ile 240	GAG Glu	CGC Arg	ATC Ile	ATA Ile	894
GAG Glu 245	GCC Ala	GAG Glu	CAG Gln	CGA Arg	GCG Ala 250	GAG Glu	ACC Thr	CAA Gln	TGC Cys	GGC Gly 255	GAT Asp	CGT Arg	GCA Ala	CTG Leu	ACG Thr 260	942
TTC Phe	CTG Leu	CGC Arg	GTT Val	GGT Gly 265	CCC Pro	TAT Tyr	TCC Ser	ACA Thr	GTC Val 270	CAG Gln	CCG Pro	GAC Asp	TAC Tyr	AAG Lys 275	GGT Gly	990
GCC Ala	GTG Val	TCG Ser	GCC Ala 280	CTG Leu	TGC Cys	CAA Gln	GTG Val	GTC Val 285	AAC Asn	AAA Lys	CAG Gln	CTC Leu	TTC Phe 290	CAG Gln	ATG Met	1038
GTC Val	GAA Glu	TAC Tyr 295	GGC Ala	CGC Arg	ATG Met	ATG Met	CCG Pro 300	CAC His	TTT Phe	GCC Ala	CAG Gln	GTG Val 305	CCG Pro	CTG Leu	GAC Asp	1086
GAC Asp	CAG Gln 310	GTG Val	ATT Ile	CTG Leu	CTG Leu	AAA Lys 315	GCC Ala	GCT Ala	TGG Trp	ATC Ile	GAG Glu 320	CTG Leu	CTC Leu	ATT Ile	GCG Ala	1134
AAC Asn 325	GTG Val	GCC Ala	TGG Trp	TGC Cys	AGC Ser 330	ATC Ile	GTT Val	TCG Ser	CTG Leu	GAT Asp 335	GAC Asp	GGC Gly	GGT Gly	GCC Ala	GGC Gly 340	1182
GGC Gly	GGG Gly	GGC Gly	GGT Gly	GGA Gly 345	CTA Leu	GGC Gly	CAC His	GAT Asp	GGC Gly 350	TCC Ser	TTT Phe	GAG Glu	CGA Arg	CGA Arg 355	TCA Ser	1230
CCG Pro	GGC Gly	CTT Leu	CAG Gln 360	CCC Pro	CAG Gln	CAG Gln	CTG Leu	TTC Phe 365	CTC Leu	AAC Asn	CAG Gln	AGC Ser	TTC Phe 370	TCG Ser	TAC Tyr	1278
CAT His	CGC Arg	AAC Asn 375	AGT Ser	GCG Ala	ATC Ile	AAA Lys	GCC Ala 380	GGT Gly	GTG Val	TCA Ser	GCC Ala	ATC Ile 385	TTC Phe	GAC Asp	CGC Arg	1326
ATA Ile	TTG Leu 390	TCG Ser	GAG Glu	CTG Leu	AGT Ser	GTA Val 395	AAG Lys	ATG Met	AAG Lys	CGG Arg	CTG Leu 400	AAT Asn	CTC Leu	GAC Asp	CGA Arg	1374
CGC Arg 405	GAG Glu	CTG Leu	TCC Ser	TGC Cys	TTG Leu 410	AAG Lys	GCC Ala	ATC Ile	ATA Ile	CTG Leu 415	TAC Tyr	AAC Asn	CCG Pro	GAC Asp	ATA Ile 420	1422
CGC Arg	GGG Gly	ATC Ile	AAG Lys	AGC Ser 425	CGG Arg	GCG Ala	GAG Glu	ATC Ile	GAG Glu 430	ATG Met	TGC Cys	CGC Arg	GAG Glu	AAG Lys 435	GTG Val	1470
TAC Tyr	GCT Ala	TGC Cys	CTG Leu 440	GAC Asp	GAG Glu	CAC His	TGC Cys	CGC Arg 445	CTG Leu	GAA Glu	CAT His	CCG Pro	GGC Gly 450	GAC Asp	GAT Asp	1518
GGA Gly	CGC Arg	TTT Phe 455	GCG Ala	CAA Gln	CTG Leu	CTG Leu	CTG Leu 460	CGT Arg	CTG Leu	CGC Arg	CGC Arg	TTT Phe 465	GCG Ala	ATC Ile	GAT Asp	1566
CAG Gln	CCT Pro 470	GAA Glu	GTG Val	CCA Pro	GGA Gly	TCA Ser 475	CCT Pro	GTT Val	CCT Pro	CTT Leu	CCG Pro 480	CAT His	TAC Tyr	CAG Gln	CGA Arg	1614

SEQ ID NO:2 [TO BE GENERATED BY PATENTIN FROM SEQ ID NO:1]

Cys - X - X - Cys - X - X - Asp* - X - Ala* - X - Gly*
 - X - Tyr* - X - X - X - X - Cys - X - X - Cys - Lys* -
 X - Phe - Phe - X - Arg* - X - X - X - X - X - X - X -
 X - X - (X - X -) Cys - X - X - X - X - X - (X - X - X
 -) Cys - X - X - X - Lys - X - X - Arg - X - X - Cys - X
 - X - Cys - Arg* - X - X - Lys* - Cys - X - X - X -
 Gly* - Met.

SEQ ID No:4	5'-AGGTCA-AGG-AGGTCA-3',
SEQ ID No:5	5'-GGGTGA-ATG-AGGACA-3',
SEQ ID No:6	5'-GGGTGA-ACG-GGGGCA-3',
SEQ ID No:7	5'-GGTTCA-CGA-GGTTCA-3',
SEQ ID No:8	5'-AGGTCA-CAGG-AGGTCA-3',
SEQ ID No:9	5'-AGGTGA-CAGG-AGGTCA-3',
SEQ ID No:10	5'-AGGTGA-CAGG-AGGACA-3',
SEQ ID No:11	5'-GGGTTA-GGGG-AGGACA-3',
SEQ ID No:12	5'-GGGTCA-TTTC-AGGTCC-3',
SEQ ID No:13	5'-AGGTCA-CCAGG-AGGTCA-3',
SEQ ID No:14	5'-AGGTGA-ACAGG-AGGTCA-3',
SEQ ID No:15	5'-GGTTCA-CCGAA-AGTTCA-3',
SEQ ID No:16	5'-GGTTCA-CCGAA-AGTTCA-3'

```

SEQ ID No:17      5'-AGGTCA-CTGAC-AGGGCA-3',
SEQ ID No:18      5'-GGGTCA-TTCAG-AGTTCA-3',
SEQ ID No:19      5'-AAGCTTAAG-GGTTCA-CCGAA-AGTTCA-CTCAGCTT-3',
SEQ ID No:20      5'-AAGCTTAAG-GGTTCA-CCGAA-AGTTCA-CTCGCATAGCTT-3',
SEQ ID No:21      5'-AAGCTTAAG-GGTTCA-CCGAA-AGTTCA-
                  CTCGCATATATTAGCTT-3',
SEQ ID NO:22      5'-AGCTCGATGG ACAAGTGCAT TGAACCCTTG AGCTACCTGT TCACGTAAC
                  TGGGAAC TTC GA,
SEQ ID NO:23      5'-CCTGCGCCAC GCGGGCCGCC GGAGCTGTG CCTG,
SEQ ID NO:24      5'-GTGGGTATG CGCCTCGAGT GCGTCGTCCC,
SEQ ID NO:25      5'-AGGACAAAGG TCA,
SEQ ID NO:26      ATTGGACAAGTGCATTGAACCCTTGCTCT
                  TAACCAAGTTCACGTAAC TTGGGAACAGAGA
SEQ ID NO:27      atgctGTGCATTGAACgtgctcga
                  tacgaCACGTAAC TTGcacgagct
SEQ ID NO:28      atgAAGTGCATTGAACCCgctcga
                  tacTTCACGTAAC TTGGGcgagct
SEQ ID NO:29      TAAAGGATCTTGACCCCAATGAACTTCTTA
                  ATTTCTAGAACTGGGGTTACTTGAAGAAT

```

That which is claimed is:

1. A multimeric receptor comprising at least one member of the steroid/thyroid superfamily of receptors and the ultraspiracle receptor.

5 2. A receptor according to claim 1 wherein said receptor is a heterodimer.

10 3. A receptor according to claim 1 wherein said receptor is a heterotrimer.

 4. A receptor according to claim 1 wherein said receptor is a heterotetramer.

15 5. A receptor according to claim 1 wherein said member of the steroid/thyroid superfamily of receptors is an insect-derived receptor.

20 6. A receptor according to claim 5 wherein said insect-derived receptor is the ecdysone receptor.

 7. A receptor according to claim 1 wherein said member of the steroid/thyroid superfamily of receptors is PPAR, VDR, TR α , TR β , RAR α , RAR β or RAR γ .

8. A method to modulate, in an expression system, the transcription activation of a gene by a member of the steroid/thyroid superfamily of receptors in the presence of ligand therefor, wherein the expression of said gene is maintained under the control of a hormone response element, said method comprising:

exposing said system to at least the dimerization domain of the ultraspiracle receptor, in an amount effective to form a multimeric complex receptor with said member of the steroid/thyroid superfamily of receptors.

9. A method according to claim 8 wherein the dimerization domain of the ultraspiracle receptor is provided by exposing said system to compound(s) and/or condition(s) which induce expression of a gene encoding said dimerization domain.

10. A method according to claim 8 wherein said member of the steroid/thyroid superfamily of receptors is EcR, PPAR, VDR, TR, or RAR.

11. A method to modulate, in an expression system, the transcription activation of a gene by a member of the steroid/thyroid superfamily of receptors in the presence of ligand therefor, and in the further presence of the ultraspiracle receptor, wherein the expression of said gene is maintained under the control of a hormone response element, said method comprising:

exposing said system to compound(s) and/or condition(s) which prevent association of said member with ultraspiracle receptor, or fragments thereof, in an amount effective to prevent said association.

12. A method according to claim 11 wherein said member of the steroid/thyroid superfamily of receptors is selected from ECR, PPAR, RAR, TR, or VDR.

5 13. A method according to claim 11 wherein said compound which prevents association of said member with the ultraspiracle receptor is an anti-ultraspiracle antibody.

10 14. A method for modulating the expression of an exogenous gene in a subject containing:

15 (i) a DNA construct encoding said exogenous gene under the control of a steroid or steroid-like hormone response element; wherein said response element is not normally present in the cells of said subject,

20 (ii) a receptor which is not normally present in the cells of said subject, wherein said receptor, in the presence of its associated ligand and the ultraspiracle receptor, binds to said steroid or steroid-like hormone response element, and

25 (iii) ultraspiracle receptor;

30 said method comprising administering to said subject an effective amount of said associated ligand; wherein said ligand is not normally present in the cells of said subject; and wherein said ligand is not toxic to said subject.

35 15. A method according to Claim 14 wherein said receptor not normally present in the cells of the subject and said ultraspiracle receptor are provided to said subject by DNA construct(s) encoding said receptors.

16. A method according to Claim 15 wherein said receptors are expressed under the control of a tissue specific promoter.

5 17. A method according to Claim 14 wherein said exogenous genes are selected from wild type genes and therapeutic genes.

10 18. A method according to Claim 17 wherein said wild type genes are selected from genes which encode gene products:

the substantial absence of which leads to the occurrence of a non-normal state in said subject; or

15 a substantial excess of which leads to the occurrence of a non-normal state in said subject.

20 19. A method according to Claim 17 wherein said therapeutic genes are selected from those which encode gene products:

which are toxic to the cells in which they are expressed; or

which impart a beneficial property to said subject.

25

00550508.031500

20. A method of inducing the expression of an exogenous gene in a subject containing:

5 (i) a DNA construct encoding an exogenous gene product under the control of a hormone response element; wherein said response element is not normally present in the cells of said subject,

10 (ii) DNA encoding a receptor which is not normally present in the cells of said subject, under the control of an inducible promoter; wherein said receptor, in the presence of its
15 associated ligand and the ultraspiracle receptor, binds to said hormone response element,

20 (iii) ultraspiracle receptor, and

(iv) the associated ligand for said receptor which is not normally present in the cells of said subject;

25 said method comprising subjecting a subject to conditions suitable to induce expression of said receptor which is not normally present in the cells of said subject.

21. A method of inducing expression of an exogenous gene product in a subject containing a DNA construct encoding said product under the control of a hormone response element; wherein said response element is
 5 not normally present in the cells of said subject, said method comprising introducing into said subject:

a receptor which is not normally present in the cells of said subject; wherein said receptor, in combination with its associated ligand and
 10 ultraspiracle receptor, binds to a hormone response element, activating transcription therefrom,

the ultraspiracle receptor, and
 15 the associated ligand for said receptor.

22. A method for the expression of recombinant products detrimental to a host organism, said method comprising:

transforming suitable host cells with:
 20 (i) a construct comprising a sequence encoding said recombinant product under the control of a hormone response element;

wherein said response element is
 25 not normally present in the cells of said host, and

(ii) DNA encoding a receptor not normally present in said host cells;

growing said host cells to the desired level in
 30 the substantial absence of hormone(s) which, in combination with said receptor, is capable of binding to said hormone response element, and

inducing expression of said recombinant product by introducing into said host cells the ultraspiracle
 35 receptor and hormone(s) which, in combination with said receptor not normally present in said host cells, bind to said response element.

5 replacing the ligand binding domain of said first
receptor with a ligand binding domain from an exogenous
receptor to produce a chimeric receptor maintained under
the control of a tissue specific promoter;
wherein said exogenous receptor and the ligand to
10 which the exogenous receptor responds are
not normally present in said host; and
wherein said exogenous receptor, in the presence
of its associated ligand, binds to a hormone
response element, thereby activating said
15 response element, and thereafter
monitoring the production of product(s) whose
expression is controlled by said first hormone receptor
when said host is exposed to ultraspiracle receptor and
ligand to which said exogenous receptor responds.

25 replacing the ligand binding domain of said
receptor with a ligand binding domain from a second
receptor;
wherein said second receptor is not normally
present in said host; and wherein the ligand
30 to which the second receptor responds is not
normally present in said host.

25. A method to determine the ligand(s) to which orphan receptor(s) responds, said method comprising:

5 monitoring a host cell containing a reporter construct and a hybrid receptor for expression of product(s) of said reporter construct upon contacting said cell with potential ligands for said orphan receptor and the ultraspiracle receptor;

10 wherein said reporter construct comprises a gene encoding a reporter molecule, operatively linked for transcription to a steroid or steroid-like hormone response element; wherein said response element is not normally present in the cells of said host;

15 wherein said hybrid receptor comprises:

20 the N-terminal domain and DNA binding domain of a member of the steroid/thyroid superfamily of receptors, wherein said member is not normally present in the host cells, and wherein said member, in the presence of its associated ligand, binds said response element, activating transcription therefrom, and

25 the ligand binding domain of said orphan receptor.

26. An isolated DNA which encodes a polypeptide, wherein said polypeptide is characterized by having a DNA binding domain of about 66 amino acids with at least 9 Cys residues, wherein said DNA binding domain has:

- 5 (a) more than about 75 % amino acid identity in comparison with the DNA binding domain of hRXR-alpha,
(b) less than about 60 % amino acid identity in comparison with the DNA
10 binding domain of hGR
(c) less than about 60% amino acid identity in comparison with the DNA binding domain of hRAR α ,

as well as functional fragments thereof.

- 15 27. A DNA according to Claim 26 wherein the polypeptide encoded by said DNA comprises a DNA binding domain with substantially the same sequence as that of amino acids 104-169 shown in SEQ ID NO:2.

- 20 28. DNA according to Claim 27 wherein the polypeptide encoded by said DNA has substantially the same sequence as that of amino acids 1-513 shown in SEQ ID NO:2.

- 25 29. DNA according to Claim 28 wherein said DNA comprises a segment with substantially the same nucleotide sequence as nucleotides 163 - 1704 shown in SEQ ID NO:1.

- 30 30. DNA according to Claim 29 which is pXR2C8.

31. An isolated polypeptide characterized by having a DNA binding domain of about 66 amino acids with at least 9 Cys residues, wherein said DNA binding domain has:

- 5 (a) more than about 75 % amino acid identity in comparison with the DNA binding domain of hRXR-alpha,
 - (b) less than about 60 % amino acid identity in comparison with the DNA binding domain of hGR,
 - 10 (c) less than about 60% amino acid identity in comparison with the DNA binding domain of hRAR α ,
- as well as functional fragments thereof.

15 32. A polypeptide according to Claim 31 wherein said polypeptide comprises a DNA binding domain with substantially the same sequence as that of amino acids 104 - 169 shown in SEQ ID NO:2.

20 33. A polypeptide according to Claim 32 wherein said polypeptide has substantially the same sequence as that of amino acids 1 - 513 shown in SEQ ID NO:2.

25 34. A polypeptide according to Claim 33 wherein said polypeptide is encoded by pXR2C8.

ABSTRACT OF THE DISCLOSURE

In accordance with the present invention, it has been discovered that various members of the steroid/thyroid superfamily of receptors can interact with the insect-derived ultraspiracle receptor, to form multimeric species. Accordingly, the interaction of at least one member of the steroid/thyroid superfamily of receptors with at least the dimerization domain of the ultraspiracle receptor modulates the ability of said member of the steroid/thyroid superfamily of receptors to trans-activate transcription of genes maintained under hormone expression control in the presence of the cognate ligand for said member of the superfamily.

00526293-015100




FIGURE 1

00540-88888888




FIGURE 2

DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION

As the below-named inventors, we hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled MULTIMERIC FORMS OF MEMBERS OF THE STEROID/THYROID SUPERFAMILY OF RECEPTORS WITH THE ULTRASPIRACLE RECEPTOR, the specification of which

_____ is attached hereto.

 X was filed on July 2, 1992 as

Application Serial No. 07/907,908

and was amended on (or amended through) _____.
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Sec. 1.56(a).

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
07/497,935	March 22, 1990	Pending

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

We hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

STEPHEN E. REITER, Registration No. 31,192; JAMES R. BRUEGGEMANN, Registration No. 28,286; ROBERT A. SCHROEDER, Registration No. 25,393; LAURENCE H. PRETTY, Registration No. 25,312; and GARY A. CLARK, Registration No. 28,060.

Direct all telephone calls to:

STEPHEN E. REITER

Telephone: (619) 546-4737

Address all correspondence to:

STEPHEN E. REITER
Pretty, Schroeder, Brueggemann & Clark
444 South Flower Street, Suite 2000
Los Angeles, California 90071

Full name of first inventor: RONALD M. EVANS

Inventor's signature: Ronald M Evans

Date: July 27, 1992

Residence: La Jolla, California

Citizenship: United States

Post Office Address: 8615 La Jolla Scenic Road, North
La Jolla, California 92037

Full name of second inventor: MICHAEL B. MC KEOWN

Inventor's signature: Michael B. McKeown

Date: 7-27-92

Residence: San Diego, California

Citizenship: United States

Post Office Address: 3083 Fried Avenue
San Diego, California 92122

Full name of third inventor: ANTHONY E. ORO

Inventor's signature: Anthony Oro

Date: 8/12/92

Residence: San Diego, California

Citizenship: United States

Post Office Address: 10710 Escobar Drive
San Diego, California 92124

Full name of fourth inventor: WILLIAM A. SEGRAVES

Inventor's signature: William A. Segraves

Date: 8/21/92

Residence: ~~San Diego, California~~ see below ~~was~~

Citizenship: United States

Post Office Address: ~~4343 Caminito del Diamante~~
~~San Diego, California 92121~~

416 Meetinghouse Rd. ~~was~~
Ambler, Pennsylvania 19002

005150-3000000

Inventor's signature:

Date: 7/28/92.

Citizenship: Taiwan

Post Office Address: 3765G Miramar Street
La Jolla, California 92037

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Evans, et al.)
)
Application No.: Unassigned)
)
Filed: March 15, 2000)
)
For: MULTIMERIC FORMS OF MEMBERS)
OF THE STEROID/THYROID)
SUPERFAMILY OF RECEPTORS)
WITH THE ULTRASPIRACLE)
RECEPTOR)
_____)

Box Patent Application
Assistant Commissioner of Patents
Washington, D.C. 20231

APPOINTMENT OF ASSOCIATE ATTORNEY

Sir:

I am attorney of record in the above-referenced patent application and, pursuant to 37
C.F.R. 1.34b, I hereby appoint:

JOSEPH R. BAKER	Registration No. 40,900
TIM ELLIS	Registration No. 41,734
LISA A. HAILE	Registration No. 38,347
WILLIAM N. HULSEY III,	Registration No. 33,402
RICHARD J. IMBRA	Registration No. 37,643
SHEILA R. KIRSCHENBAUM	Registration No. 44,835
JUNE M. LEARN	Registration No. 31,238
TIMOTHY W. LOHSE	Registration No. 35,255
TERRANCE A. MEADOR	Registration No. 30,298
JOHN OSKOREP	Registration No. 41,234
STEPHEN E. REITER	Registration No. 31,192
STEVEN R. SPRINKLE	Registration No. 40,825
RAMSEY R. STEWART	Registration No. 38,322
DAVID R. STEVENS	Registration No. 38,626
BARRY N. YOUNG	Registration No. 27,744

PATENT
Docket No.: SALK1320-3

as associate attorney of record to prosecute this application as well as any continuation and divisional applications and to transact all business in the Patent and Trademark Office in connection therewith.

Respectfully submitted,

Dated: March 15, 2000

Stephen E. Reiter
Registration No. 31,192
Telephone: (858) 677-1409
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1600
San Diego, CA 92121-2189

Gray Cary\
GT\6166835.1
62574-990000